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30th  June, 2014 
To, 
Dr. Akbar Ali Khan 
Professor 
BRAC Business School 
BRAC University 
 
Subject
 
: Submission of internship report on “Financial performance analysis of GSK with a 
comparison to few of the leading pharmaceutical companies of Bangladesh.” 
Dear Sir, 
 
This is my great pleasure to submit the internship report of my three months long internship program in 
the GlaxoSmithKline Bangladesh Limited, under Finance and Accounts Department. The title of the 
report is “Financial performance analysis of GSK with a comparison to few of the leading 
pharmaceutical companies of Bangladesh”. This report has been prepared to fulfill the requirement of 
my internship program at my assigned organization, GlaxoSmithKline Bangladesh Limited. 
I have put my best effort to make this report a successful one. It has been joyful & enlightening 
experience for me to work in the organization & prepare this report. However, this has been obviously a 
great source of learning for me to. 
I would like to express my sincere gratitude to you for your kind guidance & suggestions in preparing the 
report. It would be my immense pleasure if you find this report useful & informative to have an apparent 
perspective on the issue. I shall be happy to provide any further explanation regarding this report if 
required & please do not hesitate to call me if you have any query on this report or any other relevant 
matters. 
 
Thanks and best regards, 
Nusrat Sharmeen Anika 
ID: 10104060 
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The internship report is made on financial performance comparison among GSK, Square and 
Beximco. The report includes the process of reviewing and evaluating company’s financial 
statements, because without this the ratio analysis, vertical and horizontal analysis cannot be 
done. Ratio analysis mainly calculates the statistical relationships between data. The ratio 
analysis helps an organization to understand performance on the last fiscal year which further 
helps them to take decisions in future. 
I have selected this topic after consulting with my academic supervisor. The beginning part of 
my report contains the brief introduction of the selected company and the objectives, scope, 
methodology and limitations of the study. 
In the second part, I have covered the detailed background of the company such as the history, 
global network, mission & strategy, the organizational structure, market position and an 
overview of its operations. 
In the third part, I have shared my internship experience at Finance & Accounts Department of 
GlaxoSmithKline, Bangladesh Ltd. In this part, I have described my observation and 
understanding about the organization including my responsibilities and working experiences.  
Then starts the main analysis part of my report where I have done vertical, horizontal, 
comparative and ratio analysis of consecutive five years. Here, I have presented the result and 
according to the result, I have interpreted the financial condition of Square, Beximco and GSK 
Bangladesh Ltd. 
In the next part, I have discussed some recommendations that will help GSK to strengthen their 
financial base more. 
Lastly, I have come up with a brief conclusion and necessary references. 
 
 
 
Executive Summary 
5 
 
 
 
 
Name of the chapter Page no. 
Chapter 1: Introduction 6-7 
Chapter 2: Company Overview 8-21 
Chapter : 3 Internship Experience 22 
Chapter:4 Financial Performance Analysis 
• Vertical Analysis 
• Horizontal Analysis 
• Comparative Analysis 
• Ratio Analysis 
23-60 
Chapter : 5 Recommendation 61-62 
Chapter: 6 Conclusion 63 
 References 64 
 
 
 
 
 
 
 
Table of Contents 
6 
 
CHAPTER ONE 
 
 
1.1: OBJECTIVE OF THE REPORT 
Objective of the study entails the Financial Ratio Analysis of GlaxoSmithKline Bangladesh, Square and 
Beximco to assess their performance in the market. 
 
1.2: SCOPE 
This report is on “Financial performance analysis of GSK with a comparison to few of the leading 
pharmaceutical companies of Bangladesh”.So, this term paper mainly represents the ratio analysis, 
vertical analysis and horizontal analysis and comparative analysis of the three leading pharmaceutical 
companies to show their performance in the market. Moreover, I also tried to focus on growth rates of 
each major item in the financial statements. I think anyone can get a good idea about these three 
companies financial performance, organizations can find their lacking in performance and management 
can find some ways to improve their present performance. 
 
1.3: METHODOLOGY 
Data Collection 
In order to complete the study, two types of data have been used- 
 Primary Data  
 Secondary Data  
Primary Data was collected through direct observation and interviews with my supervisor and other 
officials of GlaxoSmithKline, Bangladesh. 
Secondary Data was collected mainly through the annual reports of GSK, Square and Beximco. 
Moreover, I also studied websites, some published reports and organizational documents.  
  
 Introduction 
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1.4: LIMITATION 
 
The security concern of GSK about revealing the information was one of the biggest challenges for me. 
For ensuring confidentiality, GSK authority was unwilling to share some information which was really 
needed to prepare the report. Their official website also contains a limited amount of information required 
for making a report and I mainly covered the information from annual reports and through the primary 
sources of data. Then the time duration for preparing the report was not enough. Due to the work load in 
the office, I also got limited time to prepare the report. 
As the internship was first practical experience for me, so it was possible for me to understand the whole 
and actual financial performance of GSK. Based on the annual reports’ data, I have used my 
understanding about finance to find out the ratios and interpret the situation. So, the statements, 
recommendations and conclusions are made according to my knowledge and level of understanding. 
In spite of having much difficulties and limitations, I have given my best effort to accomplish the report 
successfully. 
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CHAPTER TWO 
 
 
GlaxoSmithKline (GSK) is one of the leading British multinational pharmaceutical, biologics, vaccines 
and consumer healthcare company headquartered in Brentford, London. It is the world's fourth-largest 
pharmaceutical company after Pfizer, Novartis and Sanofi, measured by 2009 prescription drug sales. The 
company was established in 2000 by the merger of Glaxo Wellcome plc and SmithKline Beecham plc. 
GSK has a portfolio of products for major disease areas such as asthma, cancer, virus control, infections, 
mental health, diabetes and digestive conditions. It also has a large consumer healthcare division that 
produces oral healthcare and nutritional products, drinks and over-the-counter medicines, including 
Sensodyne, Boost and Horlicks.  GSK has a strong Research and Development which works hard to give 
best health facilities to the customers and keeps pace with the rapidly changing health care environment 
very well.GSK is headquartered in London, United Kingdom and the company sells its products in around 
70 countries. GSK has gained leadership in four major therapeutic areas which include anti invectives, 
central nervous system (CNS) and respiratory & gastro- intestinal/ metabolic. Moreover, GSK is also 
gaining leadership in the most significant areas of vaccines and it has an emerging portfolio in a very 
sensitive segment and that is oncology. It is concentrating a lot in making strong quality oncology 
products. Andrew Witty has been the chief executive officer since May 2008. The company has a primary 
listing on the London Stock Exchange and as of 6 July 2012 it had a market capitalization of 
£74.8 billion, the fifth-largest of any company listed on the London Stock Exchange.  
History of GSK and its operation throughout the world and Bangladesh is presented below: 
History of GSK 
1873 
The company was oriented as Joseph Nathan & Company in New Zealand with the founding of a small 
export-import company. It started its operation as a processing unit of abundant fresh milk of New 
Zealand. The only product it was producing Glaxo Baby Food. 
1875 
It started to export baby food to UK Alec Nathan, son of Joseph Nathan, coined the name “Glaxo” from 
“Glactose”. 
 
1924 
Joseph Nathan & Company entered the pharmaceutical industry with the manufacture of Ostelin, the first 
Vitamin D preparation. The importance of the pharmaceutical market was soon realized. 
1935 
Glaxo Laboratories Limited was founded with its headquarters at Greenford, Middlesex and London for 
the production and marketing of foods and pharmaceuticals. 
1947 
Company Overview 
 
9 
 
After the 2nd world war, Glaxo developed rapidly. Glaxo Laboratories Limited absorbed its parent Joseph 
Nathan & Company, and became a public company. 
1963 
Edinburgh Pharmaceutical Industries Limited, which owned Duncan, Flock hart and Company Limited 
and MAC Far lane Smith Limited, joined Glaxo. 
1995 
Glaxo acquired 100% share, of Wellcome PLC on May 01, 1995 and formed Glaxo Welcome PLC. 
1998 
Glaxo Wellcome achieved a number of regulatory milestones for several of its key projects, such as 
ZEFFIX for the treatment of influenza. 
2000 
Glaxo Wellcome and SmithKline Beecham merged to form GlaxoSmithKline; a worldwide research 
based pharmaceutical company. 
2002 
The first 100 million albendazole tablets are donated as part of our commitment to fight lymphatic 
filariasis. 
2004 
The Clinical Trial Register is launched, an internet site containing clinical trial data that anyone can 
access. 
2011 
Human Genome Sciences and GSK receive approval for Benlysta, the first new lupus treatment in 50 
years  
2012 
Official supplier to the Olympic and Paralympic Games, providing laboratory services for official anti-
doping measures. 
2013 
Acquired United States-based biopharmaceutical company Human Genome Sciences (HGS). HGS and 
GSK collaborated on the development of two drugs that received marketing approval, the lupus drug 
Belimumab (Benlysta) and albiglutide for type 2 diabetes.  
2014 
GSK paid $1 billion to raise its stake in its Indian pharmaceutical unit, GlaxoSmithKline 
Pharmaceuticals, to 75 percent as part of a move to focus on emerging markets.  Novartis and Glaxo 
agreed on more than $20 billion in deals, with Novartis selling its vaccine business to GSK and buying 
GSK's cancer business. 
Source: http://www.gsk.com/about-us/our-history.html 
GSK at a glance 
• One of the world's leading research-based pharmaceutical and healthcare companies.  
• Employs over 99,000 people in over 100 countries  
• Around 12,800 people work in research teams to discover new medicines.  
10 
 
• Vaccines are included in immunization campaigns in 182 countries worldwide  
• Every second- distributes more than 35 doses of Vaccines.  
• Every minute- more than 1100 prescriptions are written for GSK products  
• Every hour spends more than £300,000 (US$562,000) to find new medicines  
• January 2008 marked the tenth anniversary of their programme to help eliminate 
lymphatic filariasis (elephantiasis). Since the start of this programme they have donated 
more than 1.4 billion albendazole tablets to countries affected by LF  
• Global community investment and charitable donations were £163 million in 2009  
 Source: http://www.gsk.com.bd/about/gsk-at-a-glance.aspx 
 
Mission  
The mission statement of the business- “ Our global quest is to improve the quality of human life by 
enabling people to do more, feel better and live longer” 
Source: http://www.gsk.com.bd/mission/ 
Strategic Goal  
Our strategic intent states our business goal – “We want to become the indisputable leader in our 
industry.”  
Strategies:  
 Grow a diversified global company 
 Deliver more products of value 
 Simplify the operating model 
 Individual Empowerment 
 Building Trust 
 
Source: Annual Report 2013, GlaxoSmithKline Bangladesh Ltd. 
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Spirit  
“We undertake our quest with the enthusiasm of entrepreneurs, excited by the constant search for 
innovation. We value performance achieved with integrity. We will attain success as a world class 
leader with each and every one of our people contributing with passion and an unmatched sense 
of urgency."  
Source: Annual Report 2013, GlaxoSmithKline Bangladesh Ltd. 
Behaviors  
 Flexible Thinking 
 Continuous Improvement 
 Customer Driven 
 Developing People 
 Enable & Drive Change 
 Building Relationships 
Source: Annual Report 2013, GlaxoSmithKline Bangladesh Ltd. 
Quality Statement  
“Quality is at the heart of everything we do- from the discovery of the molecule through product 
development, manufacture, supply and sale- and vital to all the services that support our business 
performance.” 
Source: Annual Report 2013, GlaxoSmithKline Bangladesh Ltd. 
Policy  
 Safeguard people and enhance their well being 
 Protect our communities and the environment 
 Lead in what we do 
 Make continuous improvement 
 Integrate sustainability into our business 
 Be transparent with everyone 
 
Source: Annual Report 2013, GlaxoSmithKline Bangladesh Ltd. 
 
 
Values  
 Respect for people   
 Patient Focus   
 Transparency   
 Integrity  
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The GlaxoSmithKline Bangladesh Limited 
GlaxoSmithKline (GSK) Bangladesh Limited carries with it a desirable image and reputation for the past 
6 decades. A subsidiary of GlaxoSmithKline plc- one of the world's leading research-based 
pharmaceutical and healthcare companies GSK Bangladesh, continues to be committed to improving the 
quality of human life by enabling people to do more, feel better and live longer. The Company’s principle 
activities include secondary manufacture of pharmaceutical products and marketing of vaccines, 
pharmaceutical healthcare products and health food drinks. 
In 1949 the Company commenced its journey in Bangladesh with its’ corporate identity as Glaxo in 
Chittagong as an importer of products from the Glaxo Group Companies. It started spreading its spectrum 
from being an importer to a manufacturer by establishing its own manufacturing unit at Chittagong in 
1967. The facility till date is considered as one of the Centres of Excellence in Global Manufacturing & 
Supply Network of the Group.     
The global corporate mergers and acquisitions have seen the evolution of the Company’s identity in the 
past 6 decades. In line with mergers and acquisitions, the identity changed from Glaxo to Glaxo 
Wellcome Bangladesh Limited following the Burroughs Wellcome acquisition in 1995 and finally to 
GlaxoSmithKline Bangladesh Limited during 2002 after merger with SmithKlineBeecham in December 
2000. The mega merger of the Company enables it to deliver cutting edge advancements in health care 
solutions. The relentless commitment, setting of standards of ethical standards and quality backed leading 
edge technology of the Company has built a strong relationship between the stakeholders and GSK 
Bangladesh. With the ever committed 615 numbers of personnel all over the country GSK Bangladesh, 
which now comprises of both Pharma and Consumer, continually strive to meet the GlaxoSmithKline 
mission to improve the quality of human life by ensuring healthcare products, health drinks and different 
corporporate social responsibility programs. GSK is committed to developing new and effective 
healthcare solutions. The values on which the group was founded have always inspired growth and will 
continue to do so in times to come. 
History of GlaxoSmithKline, Bangladesh Limited 
 
1948-1950 
Glaxo Laboratories (Pakistan) Limited was incorporated having its registered office in Karachi. Initially it 
was a wholly owned subsidiary of Glaxo Group Limited. 
1949: First branch in East Pakistan was opened at Dewanhat, Chittagong. The Company was absolutely 
dependent on imports from U.K. Mode of delivery of products were mainly railway parcel and post 
parcel. 
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1951-1959 
1951: Public offer of shares was made at the request of the Govt. As a result Glaxo Group’s Shareholding 
ratio reduced to 70%. 
1955: Karachi factory started production of medicines having sufficient capacity to cover market needs of 
both East and West Pakistan. 
1956: Second branch in East Pakistan was opened at Motijheel, Dhaka. 
1960-1969 
1960-1961: Permission for establishment of a factory at Chittagong was obtained from the Govt. Land for 
Fauzderhat factory was purchased. 
1962: Plan for factory building at Fauzderhat was passed by Chittagong Divisional Commissioner. 
1966:Third branch was opened at Khan Jahan Ali Road, Khulna. East Pakistan Head Office was 
established headed by one Resident Director. 
1967: Chittagong factory went into production. 
1968: Permission for packing of 1800 tons baby food and 900 tons Glaxose-D was granted by the Govt. 
1970-1979 
1970: Packing of Glaxose-D started. 
1972: All establishments of Glaxo Laboratoies (Pakistan) Ltd. in the then East Pakistan was vested in the 
abandoned properties of the Government. 
1973: Released from abandoned properties and permission was given by the Government to form a 
Company in Bangladesh. Packing of milk food commenced. 
1974: Glaxo Bangladesh Limited was incorporated and the First Depot was opened at Bogra. 
1975Depots at Barisal and Sylhet were opened. 
1976: Depot at Mymensingh was opened. 
1980-1989 
1980: Sales Depots at Comilla, Pabna and Rangpur were opened. 
1981: Sales Depot at Narayanganj was opened. 
1982: To comply with the requirements of Drugs Control Ordinance the Company had to discontinue 
production of all vitamin preparations (Tablet, Syrup & Injections) and some other products declared as 
non-essential items. Effect on sale was about 25%. Excise duty on medicine was imposed by the 
Government. 
1983: Sales Depots at Rajshahi, Tangail and Dinajpur were opened. 
1984: Sales Depots at Faridpur, Tangalil and Dinajpur were opened. 
1985: The Company discontinued packing of baby food. 
1988: Company’s registered office was re-located to Dhaka. 
1990-1999 
1990: Company properties at Paribag and Gulshan Dhaka were sold and registered office relocated to 
Chittagong. 
1995: Renamed as Glaxo Wellcome Bangladesh Limited following the Burroughs Wellcome acquisition 
2000-2010 
2002: Following the global mega merger with SmithKlineBeecham  Identity changed to GlaxoSmithKline 
Bangladesh Limited 
 
 
Source: http://www.gsk.com.bd/about/our-company.aspx 
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Operations in Bangladesh 
Operations in Bangladesh  
Headquarter Registered Office & Factory 
GlaxoSmithKline, Bangladesh LTD Fauzderhat Industrial Area 
Corporate Office North Kattali, Chittagong 
House # 2A, Road # 138 District Marketing Office 
Gulshan-1  
Ownership 
Before 1951, Glaxo Group Limited had ownership of the company all by themselves. In 1951, public 
offer of shares was made at the request of the government. As a result, Glaxo group’s shareholding 
reduced to 70%. In 1974, Glaxo Bangladesh limited was incorporated and started issuing shares by initial 
public offering. Below is the scenario of the ownership percentage from the year 2008 to 2012. 
 
Source: Annual Report (2008-2012), GlaxoSmithKline Bangladesh Limited 
Classification of shareholders by holding 
 
Source: Annual Report (2008-2012), GlaxoSmithKline Bangladesh Limited 
% of Holdings No. of shares % of Holdings No. of shares % of Holdings No. of shares % of Holdings No. of shares % of Holdings No. of shares
Setfirst Limited, UK 81.98 9,875,144           81.98 9,875,144           81.98 9,875,144          81.98 9,875,144          81.98 9,875,144           
Investment corporation of 
Bangladesh (ICB) & ICB unit and 
Mutual Funds 15.59 1,878,025           12.09 1,456,225           12.48 1,502,975          12.01 1,446,725          12.1 1,457,025           
General Public 1.61 193,543              4.06 488,543              4.45 536,343             4.58 551,393              3.7 445,956              
Sadharan Bima Corporation 0.63 76,437                 0.63 76,437                 0.63 76,437               0.63 76,437                0.63 76,437                 
Other local Financial Institutions 0.19 23,300                 1.24 150,100              0.46 55,550               0.8 96,750                1.59 191,887              
Total 100 12,046,449         100 12,046,449         100 12,046,449       100 12,046,449        100 12,046,449         
2008 2009 2010 2011 2012
No. of holders Total holdings % No. of holders Total holdings % No. of holders Total holdings % No. of holders Total holdings % No. of holders Total holdings %
Holdings 2008 2009 2010 2011 2012
Less than 500 shares 534 0.52 709 0.75 1249 1.21 897 0.89 839 0.83
500 to 5,000 shares 99 1.01 171 1.87 178 1.65 138 1.5 141 1.52
5,001 to 10,000 shares 4 0.22 13 0.8 15 0.97 14 0.86 19 1.13
10,001 to 20,000 shares 3 0.31 6 0.66 6 0.51 3 0.27 4 0.43
20,001 to 30,000 shares 0 0 2 0.38 3 0.64 4 0.77 2 0.36
30,001 to 40,000 shares 1 0.3 0 0 0 0 1 0.29 1 0.33
40,001 to 50,000 shares 0 0 1 0.4 0 0 0 0 0 0
50,001 to 1,00,000 shares 1 0.63 3 2.06 3 1.75 4 1.05 2 1.43
100,001 to 1,000,000 shares 3 15.03 3 11.1 3 11.29 2 12.39 3 11.99
Over 1,000,000 shares 1 81.98 1 81.98 1 81.98 1 81.98 1 81.98
Total 646 100 909 100 1458 100 1064 100 1012 100
15 
 
 
GSK’s market share and position comparison: 
 
 
 
 
 
 
 
 
 
Source:http://mydreamlan.wordpress.com/2013/05/12/list-of-pharmaceutical-companies-and-top-
pharmaceutical-companies-of-bangladesh-2013/ 
From the chart above, we can see that, GSK Bangladesh is securing 12th position according to data 
collected from 2013. Though having a very good position in the worldwide pharmaceutical market, GSK 
Bangladesh is not having a good position in holding a good market share in Bangladesh for its 
pharmaceutical products. From the sales revenue of GSK Bangladesh over the last five years we can see 
that, it has been generating more revenues in consumer healthcare products rather than in pharmaceutical 
products. This has diluted its position in the pharmaceutical industry of Bangladesh. The chart below 
shows its sales revenues over few years. (Source: List of pharmaceutical companies and top 
pharmaceutical companies of Bangladesh, 2013) 
District Marketing Offices: GlaxoSmithKline Bangladesh Limited has twelve District Marketing 
Offices (DMO) throughout the country which covers six zones to sell products of GSK. The locations of 
DMOs are shown below- 
Zone DMO 
Dhaka Dhaka, Mymensing 
Chittagong Chittagong, Maijdee 
Comilla Comilla, Sylhet 
Bogra Bogra, Rajshahi, Rangpur 
Khulna Khulna, Jessore 
Barisal Barisal 
Serial Name of Pharma Tk 
(Crore) 
Market   
Share 
Rank Total Market 7,186 100.00 
1 SQUARE 1,378 19.18 
2 INCEPTA PHARMA 650 9.05 
3 BEXIMCO 620 8.62 
4 OPSONIN PHARMA 355 4.94 
5 ESKAYEF 348 4.84 
6 RENATA 340 4.73 
7 ACME 319 4.44 
8 A.C.I. 293 4.08 
9 ARISTOPHARMA 286 3.99 
10 DRUG INTERNATIONAL 270 3.75 
11 SANOFI AVENTIS 185 2.57 
12 GLAXOSMITHKLINE 140 1.95 
13 ORION PHARMA LTD. 140 1.94 
16 
 
 
 
 
 
 
 
 
Distribution channel: 
 Mutual Food Distributor of consumer health care product of GSK, Bangladesh. 
 Zuellig Pharma Distributor of pharmaceuticals product of GSK, Bangladesh. 
 
 
Organizational structure of Company 
Top management: As per provisions of the Article of Association, Board of Directors holds periodic 
meetings to resolve issue of policies and strategies, recording minutes/decisions for implementation by 
the Executive Management. 
 Executive Management: 
The Managing Director heads the Executive Management, the Chief Executive Officer (CEO) who has 
been delegated necessary and adequate authority by the Board of Directors. The Executive 
Management operates through further delegations of authority at every echelon of the line 
management. 
 
Board of Directors 
Mr. Rodrigo Becker Chairman 
M. Azizul Haque Managing Director 
Mr. Fayekuzzaman Non-Executive Director & Member, Audit Committee  
Sarwar Azam khan Finance Director & Company Secretary 
Masud Khan Non-Executive Director 
Rajib Barua Site Director 
                                 Gopalakrishnan Venkatramani General Manager 
Source: http://www.gsk.com.bd/about/our-strategy.aspx 
17 
 
 
 
Organogram of GSK Bangladesh: 
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Functional Department of GlaxoSmithKline Bangladesh Ltd 
GlaxoSmithKline, Bangladesh, Limited comprises of five major departments. They are given below- 
 Human Resources  
 Marketing  
 Finance  
 Medical and regulatory affairs  
 Information Technology  
Each department of GSK operates in different aspects but they are inter-related as well as complementary 
to each other. Above mentioned functional departments are worked under the Managing Director. The 
company’s delegation of authority is decentralized. The main functions of these departments are shown 
below- 
 
HR department is one of the most active departments in GSK. Previously this department was known as 
“Personnel Management” department. The company places great emphasis and commitment in 
developing the human resources as the management body believes that only the best people with 
professional competencies can contribute successfully to achieve the organization’s goals. GSK has two 
HR Division, one is at corporate head office and other one is Chittagong factory office. There are four 
functional sub-departments. They are- HR Development, HR Services, HR Administration and Industrial 
Relations. First three sub departments are looked after by corporate head office HR division and last one 
is looked after by Chittagong HR division. There are various functions of HR department of GSK. The 
main activities of this department are given below- 
Human Resources 
1. Recruiting and training the best pool of employees according to company’s requirement  
2. Administering smooth workflow in the organization  
3. Managing demands of the labors in the factory  
4. Allocating annual holidays  
5. Organizing motivational programs for employees  
6. Looking after the wage structures and bonuses  
 
The pharmaceutical industry of Bangladesh has limited field for marketing. Yet in an age of high 
competition like todays, firms are heavily spending and effectively practicing marketing. The summary 
of marketing functions is given below 
Marketing 
1. Designing and implementing sales strategies  
2. Controlling and updating distribution network  
3. Designing and carrying out promotional programs  
19 
 
4. Providing marketing information services  
5. Carrying out different awareness programs  
6. Controlling international trades  
7. Keeping records of data regarding marketing activities  
8. Building up public communication network  
9. Looking after all the brands and patents  
10. Conducting marketing surveys as needed  
 
GSK gives proper importance to their finance department The financial statements of GSK have been 
prepared in accordance with Bangladesh Accounting Standards and the relevant requirements of the 
schedule to the Securities and Exchange Rules, 1987 and of the companies Act 1994 following the 
historical cost conversion. The primary tasks of finance department are given below- 
Finance 
1. Controlling the accounts  
2. Completing annual budgets  
3. Allocating all kinds of payments to the staffs and managers  
4. Looking after all the revenue and expenses  
5. Conducting internal audit  
6. Keeping records through IT 
7. Facilitating local production costs  
 
Medical and Regulatory Department of GSK, Bangladesh is compiled with required number of doctors 
and qualified people. This department is primarily responsible to perform tasks like liaison with 
government for legal issue purpose, communicate with doctors, handling advertisements, etc. 
Medical and regulatory affairs  
 
The technical department of GSK is extraordinarily strong. The organization always strives for reaching 
the global standard of applications of information technology. This company is one of the very few 
companies in Bangladesh that use world class sophisticated software. 
Information Technology 
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SWOT analysis: SWOT is the short form for Strengths, Weaknesses, Opportunities and Threats.  SWOT 
is a basic, straightforward model that assesses what an organization can and cannot do as well as its 
potential opportunities and threats. It includes- 
 Factors pertaining to the internal environment of the company. These are usually expressed as 
Strengths (S) or Weaknesses (W).
 Factors pertaining to the external environment of the company. These are expressed as 
Opportunities (O) or Threats (T). 
 
SWOT Analysis with points on GlaxoSmithKline, Bangladesh: 
Strengths: 
1. Highly developed and reputed Research and Development department 
2. Considerable financial resources to grow the business. 
3. Goodwill of the company and follows GMR-Good Manufacturing Practice 
4. Efficient, capable and honest workforce 
5. Ability to take advantage of economies of scale 
6. Better product quality relative to rivals 
Weaknesses: 
1. Not so large sales force relative to its competitors 
2. Underutilized plant capacity 
3. Lack of sufficient promotional effort. 
4. Higher unit cost and higher cost of production due to purchasing raw materials from specific 
sources only. 
Opportunities: 
1. Market is significantly large and growing 
2. In Bangladesh, GSK can have the advantage of cheap labor 
3. Expanding the company’s product line to meet a broader range of customer needs. 
4. Strategic agreements with other pharmaceutical companies and organizations to boost its 
research. 
5. Target and acquire untapped market for vaccines. 
Threats: 
1. Competitors products at low price 
2. Increasing threats from local competitors 
3. Political instability in the country and sudden trade policies of the government. 
4. Adverse shifts in foreign exchange rates 
5. Economic slowdown  
Source: http://empire-capital.org/wp-content/uploads/2013/11/glaxosmithkline.pdf 
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Square Pharmaceuticals Limited: 
Square Pharmaceuticals, a part of Square group of companies, is one of the leading pharmaceutical 
companies of Bangladesh. It was founded back in 1958 by Samson H. Chowdhury along with three of his 
friends as a private firm. It got licensing Agreement signed with F. Hoffmann-La Roche Ltd, Switzerland 
in 1982. Square Pharmaceuticals Ltd., the flagship company, is holding the strong leadership position in 
the pharmaceutical industry of Bangladesh since 1985 and it has been continuously in the 1st position 
among all national and multinational companies since 1985. Square Pharmaceuticals is now on its way to 
becoming a high performance global player. It pioneered exports of medicines from Bangladesh in 1987 
and has been exporting antibiotics and other pharmaceutical products to different countries of Europe, 
Asia, Africa and South America very successfully. It went public in 1991 and is currently listed on the 
Dhaka Stock Exchange. As per vision, mission and objectives; they are to emphasize on the quality of 
product, process and services leading to growth of the company imbibed with good governance. 
Mission: “Our Mission is to produce and provide quality & innovative healthcare relief for people, 
maintain stringently ethical standard in business operation also ensuring benefit to the shareholders, 
stakeholders and the society at large”. 
Source: http://en.wikipedia.org/wiki/Square_Pharmaceuticals 
Beximco Pharmaceuticals Limited: 
Beximco pharmaceuticals, a part of the Beximco group of companies, is a leading manufacturer of 
pharmaceutical formulations and Active Pharmaceutical Ingredients (APIs) in Bangladesh. It is the 
flagship company of Beximco Group, the largest private sector industrial conglomerate in Bangladesh. It 
is the only pharma company in the country which has won the National Export Gold Trophy for four 
times which is the highest recognition for the companies in the export sector for significant contribution 
to Bangladesh's economic growth. It also has unique distinction as the only Bangladeshi company to get 
listed on the AIM of London Stock Exchange. It was founded back in 1976 and started operations in 
1980, manufacturing products under the licenses of Bayer AG of Germany and Upjohn Inc. of USA. It 
has now grown to become a leading pharmaceutical company in Bangladesh, and it supplies more than 
10% of country's total medicinal needs. Today it manufactures and markets its own branded generics for 
several diseases including AIDS, cancer, asthma, hypertension, and diabetes for both national and 
international markets. The company is consistently building upon its portfolio and currently producing 
more than 500 products in different dosage forms. 
Mission: “We are committed to enhancing human health and well being by providing contemporary and 
affordable medicines, manufactured in full compliance with global quality standards. We continually 
strive to improve our core capabilities to address the unmet medical needs of the patients and to deliver 
outstanding results for our shareholders”. 
Source: http://en.wikipedia.org/wiki/Beximco_Pharma 
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CHAPTER THREE 
 
The budget book of GSK is prepared on an annual basis. For each year’s budget, preparation gets started 
from the previous year and finally the budget book for that year is published in the first quarter of that 
year. For example-the budget book preparation for 2014 started from fourth quarter of 2013 and finally it 
got published in March 2014. The details of the budget book is provided on quarter basis and then on 
month basis within those quarters. As I have worked under the supervision of the management reporting 
manager, I have seen following are the activities which are covered by him. The activities done by the 
management reporting manager related to the preparation of the budget book: 
Preparing budget book: 
• Firstly, the budget book contains pricing, financial statements, sales analysis, capital and other 
operating expenses, product profitability statements etc. 
• From the pharmaceutical products, some products are local and some are imported. Prices of each 
of the products are fixed at first and then the financial statement analysis is carried out. 
• In financial statement analysis, income statement and gross profit growth percentage analysis are 
considered as very important. Here, the variation in previous year’s actual and budgeted 
performance is also shown.  
• In sales analysis, budget for each month’s sales is considered. For each month, both monthly and 
cumulative sales analysis is done to show both sales volume and sales value.  
•  Then, there is a section where the employee headcount is provided counting the headquarter 
employees as well as factory ones. Headcount summary is also included to show total number of 
employees in each functions like- marketing, distribution, Medical administration etc. 
• In the next section, the capital expenses regarding these areas- Advertising and promotional, field 
force, product management, finance and accounts, HR, medical administration, legal and 
secretarial, communication, IT and risk and compliance are provided. 
• Finally, the product profitability statement and production cost sheet based on budget volume, 
unit cost, quality requirement are provided. 
Every month GlaxoSmithKline needs to submit their performance report to an internationally used system 
named, Unison. GSK’s in all over the world share this system to share their performances with each other. 
Basically, these are the items which are shared:  Sales and standard costs, Profit and loss. 
Unison reporting: 
Internship Experience 
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CHAPTER FOUR 
 
 
In my report, I tried to analyze the financial performance of three pharmaceutical companies 
GlaxoSmithKline Bangladesh, Square and Beximco to see how they are performing in the market and 
their position in the industry. For analysis, I have collected most of the datas from annual reports and then 
I organized the datas to carry out vertical analysis, horizontal analysis, comparative analysis and finally 
ratio analysis.  
 
 
 
 
 Vertical analysis:  
“Vertical analysis uses percentages to compare individual components of financial statements to a key 
statement figure. Horizontal analysis compares items over many time periods; vertical analysis compares 
many items within the same time period”. 
Source: McgrawHillHigher Education, Chapter 13: Financial Statement Analysis, Pg : 680 
Here, I have shown all the amounts of an income statement and balance sheets as a percentage of net sales 
and total assets respectively. 
 Horizontal analysis: 
“Financial statement users conduct comparative financial statement analysis by setting consecutive 
balance sheet, income statements or cash flow statements side by side, and reviewing changes in 
individual categories on a year to year or multi year basis. It is also referred to horizontal analysis.” 
Source: Leopold A.  Bernstein, John J. Wild, Financial statement analysis, Chapter-1: Financial 
statement analysis and reporting, Pg : 22 
Financial Performance Analysis 
 
Financial 
Performance 
Analysis 
Vertical Analysis 
Horizontal Analysis 
Comparative Analysis 
Ratio Analysis 
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Here, I have shown the horizontal analysis among GSK, Square and Beximco to understand each of the 
company’s growth rates in each element of both Income statements and Balance sheets.  
 Comparative analysis: 
In the comparative analysis section, I have shown the comparison among basic elements of the income 
statement and the balace sheet. It has been done to show a comparative scenario among the three 
companies’ performance in net sales, cost of goods sold, gross profit, operating expenses, net income, 
total assets, total equity and total liabilities. Here, total assets, total equity and total liabilities belong to 
balance sheet items and the rest of the elements are from the income statement. 
 Ratio analysis: 
“Ratio analysis involves studying various relationships between different items reported in a set of 
financial statements.” 
Source: McgrawHillHigher Education, Chapter 13: Financial Statement Analysis, Pg : 680 
Ratio analysis is used to evaluate various aspects of a company’s operating and financial performance 
such as its efficiency, liquidity, profitability and solvency. The trend of these ratios over time is studied to 
check whether they are improving or deteriorating. Here, I have used ratio analysis among three 
companies to see their individual performance and position. Ratio analysis is a cornerstone of 
fundamental financial analysis.  
Here I have used the following ratios to compare the three companies’ performance over years. 
 Current ratio 
 Quick ratio 
 Cash ratio 
 Gross profit margin 
 Operating profit margin 
 Net profit margin 
 Return on Asset 
 Return on Equity 
 Asset turnover 
 Inventory turnover 
 Earning per share 
 Debt ratio 
 Debt to equity ratio 
 Days sales outstanding 
 Dividend payout ratio & 
 Price earnings ratio 
  
 1. 
Vertical analysis compares different items to a single item in the same accounting period. This technique is 
also known as common size financial statements analysis. Vertical analysis can be done for both income 
statement and balance sheet. Here, all the amounts in the income statement are shown as a percentage of net 
sales or the net revenue. 
Vertical analysis: 
 
               The chart shows the vertical analysis of Square’s Income statement where all the components of the income 
statement has been compared as a percentage of net sales or net revenues. The basic performance indicators 
like-Cost of goods sold shows that it was quite same in early four years but declined in the final year 2012. 
Due to the decrease in COGS in 2012, the gross profit increased to some extent. By excluding all the expenses, 
interests and taxes, the final performance indicator total comprehensive income shows that, it was highest in 
2010 which is 19.48%. The lowest rate can be seen in 2012. All the other percentages are shown in the chart. 
Income Statement Vertical analysis (Square Pharma)
2008 2009 2010 2011 2012
Amount % Amount % Amount % Amount % Amount %
Net sales 9,82,07,96,568      100.00% 11,46,25,78,410      100.00% 13,47,14,24,469      100.00% 16,05,44,25,243      100.00% 17,95,94,89,496       100.00%
COGS 5,67,25,65,973      57.76% 6,56,12,88,485        57.24% 7,70,36,61,010         57.19% 9,16,72,53,620        57.10% 10,22,34,78,073       56.93%
Gross Profit 4,14,82,30,595      42.24% 4,90,12,89,925        42.76% 5,76,77,63,459         42.81% 6,88,71,71,623        42.90% 7,73,60,11,423         43.07%
Operating expenses 2,17,69,29,331      22.17% 2,52,05,32,046        21.99% 3,01,61,58,062         22.39% 3,56,60,24,910        22.21% 3,88,32,00,849         21.62%
Selling and Distribution expenses 1,31,93,62,317      13.43% 1,68,72,10,447         14.72% 2,12,11,63,004         15.75% 2,43,04,66,795        15.14% 2,82,05,82,797          15.71%
Administrative expenses 46,04,31,051         4.69% 52,44,60,492            4.58% 62,61,45,987            4.65% 70,19,77,079            4.37% 73,73,37,036             4.11%
Financial expenses 39,71,35,963         4.04% 30,88,61,107            2.69% 26,88,49,071            2.00% 43,35,81,036            2.70% 32,52,81,016             1.81%
Profit from operations 1,97,13,01,264      20.07% 2,38,07,57,879        20.77% 2,75,16,05,397         20.43% 3,32,11,46,713        20.69% 3,85,28,10,574         21.45%
Other income 66,55,20,915         6.78% 58,55,64,826            5.11% 83,38,84,528            6.19% 85,67,39,329            5.34% 85,22,89,241             4.75%
Profit before WPPF 2,63,68,22,179      26.85% 2,96,63,22,705         25.88% 3,58,54,89,925         26.62% 4,17,78,86,042        26.02% 4,70,50,99,815          26.20%
Allocations for WPPF 12,55,62,961         1.28% 14,12,53,462            1.23% 17,07,37,615            1.27% 19,89,46,954            1.24% 22,40,52,372             1.25%
Profit before Tax 2,51,12,59,218      25.57% 2,82,50,69,243         24.65% 3,41,47,52,310         25.35% 3,97,89,39,088        24.78% 4,48,10,47,443          24.95%
Provision for Income Tax 59,26,44,226         6.03% 68,84,99,602            6.01% 80,55,75,198            5.98% 95,89,06,349            5.97% 1,06,77,70,353          5.95%
Provision for Deferred Income Tax 2,85,62,063           0.29% 4,86,97,850              0.42% 7,71,22,562               0.57% 12,23,22,098            0.76% 7,18,52,307               0.40%
Profit after Tax 1,89,00,52,929      19.25% 2,08,78,71,791        18.21% 2,53,20,54,550         18.80% 2,89,77,10,641        18.05% 3,34,14,24,783         18.61%
Other comprehensive Income: -                           -                              
Gain on marketable securities -                           -                              9,24,83,089               0.69% 13,99,86,324            0.87% 10,14,75,954             0.57%
Total comprehensive Income 1,89,00,52,929      19.25% 2,08,78,71,791        18.21% 2,62,45,37,639         19.48% 3,03,76,96,965        18.92% 3,23,99,48,829         18.04%
EPS 125.25                    138.36                       129.07                       147.71                       9.01                            
Number of shares used to compute EPS 1,50,90,300           1,50,90,300              1,96,17,390              1,96,17,390              37,07,68,664             
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The vertical analysis of Square shows all the components as a percentage of total assets or total liabilities and 
equity amount. The chart shows that, the basic performance indicators of the income statement like- non-
current assets are seen to be highest (74.43%) in 2012 and the lowest (63.89%) in 2010. Here, all the non-
current assets of different years have been shown as a percentage of total assets. So, square had the highest rate 
of non-current assets of all assets in 2012 and the lowest rate in 2010. From current assets, we can see that, the 
highest percentage (36.11%) was in 2010 and lowest (25.57%) was in 2012. From shareholders’ equity, we can 
see that the highest rate was in 2012 (80.37%) and lowest (71.06%) in 2010. The rest of the percentages 
belonged to another element, liabilities (current and non-current). 
 
 
 
Balance Sheet Vertical analysis (Square Pharma)
2008 2009 2010 2011 2012
ASSETS: Amount % Amount % Amount % Amount % Amount %
Non-Current Assets: 9,40,77,30,001      71.00% 10,25,51,89,084      68.23% 12,42,21,95,814      63.89% 14,70,82,77,754  68.56% 17,45,09,47,962       74.43%
Property, Plant and Equipment-Carrying Value 4,89,96,79,832      36.98% 5,63,07,91,822         37.46% 6,98,15,59,781         35.91% 8,76,78,27,062     40.87% 9,32,21,86,497          39.76%
Capital Work-in-Progress -                           0.00% 63,43,47,093            4.22% 88,75,84,197            4.56% 1,27,43,90,572     5.94% 3,71,83,26,254          15.86%
Investment - Long Term (at Cost) 4,50,80,50,169      34.02% 3,99,00,50,169         26.55% 4,03,17,51,281         20.73% 3,97,10,22,723     18.51% 3,82,11,21,331          16.30%
Investment in Marketable Securities (Fair Value) 52,13,00,555            2.68% 69,50,37,397        3.24% 58,93,13,880             2.51%
Current Assets: 3,84,35,12,855      29.00% 4,77,43,11,194        31.77% 7,02,22,13,840         36.11% 6,74,55,07,008    31.44% 5,99,66,97,544         25.57%
Inventories 2,09,87,55,231      15.84% 2,20,70,78,082         14.68% 2,54,16,88,329         13.07% 2,68,78,18,472     12.53% 2,50,36,83,240          10.68%
Trade Debtors 47,75,62,002         3.60% 50,82,49,174            3.38% 77,24,21,345            3.97% 80,83,11,714        3.77% 80,09,74,912             3.42%
Advances,Deposits and Prepayments 26,03,30,162         1.96% 35,82,50,076            2.38% 52,39,91,079            2.69% 57,71,56,445        2.69% 65,03,80,369             2.77%
Investment in marketable securities(at cost) 2,02,50,000           0.15% 22,12,69,226            1.47%
Short Term Loan 69,31,57,720         5.23% 1,22,07,36,941         8.12% 2,81,38,11,332         14.47% 2,08,53,00,110     9.72% 1,10,92,51,152          4.73%
Cash and Cash Equivalents 29,34,57,740         2.21% 25,87,27,695            1.72% 37,03,01,755            1.90% 58,69,20,267        2.74% 93,24,07,871             3.98%
TOTAL ASSETS 13,25,12,42,856   100.00% 15,02,95,00,278      100.00% 19,44,44,09,654      100.00% 21,45,37,84,762  100.00% 23,44,76,45,506       100.00%
SHAREHOLDERS' EQUITY AND LIABILITIES:
Shareholders' Equity: 9,94,93,97,634      75.08% 11,55,43,79,825      76.88% 13,81,77,05,990      71.06% 16,26,68,84,255  75.82% 18,84,47,46,184       80.37%
Share Capital 1,20,72,24,000      9.11% 1,50,90,30,000         10.04% 1,96,17,39,000         10.09% 2,64,83,47,600     12.34% 3,70,76,86,640          15.81%
Share Premium 2,03,54,65,000      15.36% 2,03,54,65,000         13.54% 2,03,54,65,000         10.47% 2,03,54,65,000     9.49% 2,03,54,65,000          8.68%
General Reserve 10,58,78,200         0.80% 10,58,78,200            0.70% 10,58,75,200            0.54% 10,58,78,200        0.49% 10,58,78,200             0.45%
Tax Holiday Reserve 1,10,19,35,237      8.32% 1,10,19,35,237         7.33% 1,10,19,35,237         5.67% -                         0.00%
Gain on Marketable Securities (Unrealized) 25,94,35,115            1.33% 39,94,21,439        1.86% 29,79,45,485             1.27%
Retained Earnings 5,49,88,95,197      41.50% 6,80,20,71,388         45.26% 8,35,32,56,438         42.96% 11,07,77,72,016  51.64% 12,69,77,70,859       54.15%
Non-Current Liabilities: 66,09,76,668         4.99% 1,25,83,76,052        8.37% 95,85,11,238            4.93% 93,39,65,662        4.35% 81,04,61,067             3.46%
Long Term Loans - Secured 44,97,57,608         3.39% 1,03,26,33,110         6.87% 65,56,45,734            3.37% 50,87,78,060        2.37% 31,34,21,158             1.34%
Deferred Tax Liability 21,12,19,060         1.59% 22,57,42,942            1.50% 30,28,65,504            1.56% 42,51,87,602        1.98% 49,70,39,909             2.12%
Current Liabilities: 2,64,08,68,554      19.93% 2,21,67,44,401        14.75% 4,66,81,89,426         24.01% 4,25,29,34,845    19.82% 3,79,24,38,255         16.17%
Short Term Bank Loans 1,53,43,45,782      11.58% 73,64,43,848            4.90% 2,62,74,83,864         13.51% 2,01,65,51,125     9.40% 1,11,26,94,131          4.75%
Long Term Loans - Current Portion 29,55,90,601         2.23% 46,20,90,211            3.07% 47,81,99,933            2.46% 47,71,41,480        2.22% 51,15,04,034             2.18%
Trade Creditors 12,42,22,699         0.94% 39,47,15,915            2.63% 73,33,69,218            3.77% 87,54,31,555        4.08% 1,08,60,97,881          4.63%
Liabilities for Expenses 6,95,73,702           0.53% 5,64,63,570              0.38% 7,94,99,584               0.41% 9,53,61,435          0.44% 10,96,04,834             0.47%
Liabilities for Other Finance 61,71,35,770         4.66% 56,70,30,857            3.77% 74,96,36,827            3.86% 78,84,49,250        3.68% 97,25,37,375             4.15%
Total Liabilities: 3,30,18,45,222      24.92% 3,47,51,20,453        23.12% 5,62,67,00,664         28.94% 5,18,69,00,507    24.18% 4,60,28,99,322         19.63%
TOTAL SHAREHOLDERS' EQUITY AND LIABILITIES 13,25,12,42,856   100.00% 15,02,95,00,278      100.00% 19,44,44,06,654      100.00% 21,45,37,84,762  100.00% 23,44,76,45,506       100.00%
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The chart shows the vertical analysis of Beximco where all the components of the income statement has been 
calculated as a percentage of net sales or net revenues. The basic performance indicators like-Cost of goods 
sold shows that it was the lowest in 2008 which is 49.94% and highest in 52.75% in 2012. Because of being 
the lowest rate in 2008 and highest in 2012 respectively, the gross profit was highest in 2008 and lowest in 
2012. By excluding all the expenses, interests and taxes, the final performance indicator total comprehensive 
income shows that, it was highest in 2010 which is 16.20%. The lowest rate can be seen in 2009. All the other 
percentages are shown in the chart. 
 
 
 
 
 
Income Statement Vertical analysis (Beximco Pharma)
2008 2009 2010 2011 2012
Amount % Amount % Amount % Amount % Amount %
Net Sales Revenue 4,01,01,67,059      100.00% 4,86,82,54,915        100.00% 6,49,08,47,353         100.00% 7,89,02,41,843    100.00% 9,28,91,15,284         100.00%
Cost of Goods Sold 2,00,28,71,181      49.94% 2,56,62,06,626        52.71% 3,31,76,40,254         51.11% 4,10,37,09,021    52.01% 4,89,97,13,857         52.75%
Gross Profit 2,00,72,95,878      50.06% 2,30,20,48,289        47.29% 3,17,32,07,099         48.89% 3,78,65,32,822    47.99% 4,38,94,01,427         47.25%
Operating Expenses 1,00,85,01,030      25.15% 1,30,07,65,878        26.72% 1,53,74,26,907         23.69% 1,79,80,53,124    22.79% 2,18,15,21,867         23.48%
Administrative Expenses 15,34,64,243         3.83% 21,51,92,547            4.42% 23,34,13,980            3.60% 27,52,01,846        3.49% 33,22,25,347             3.58%
Selling, Marketing and Distribution Expenses 85,50,36,787         21.32% 1,08,55,73,331         22.30% 1,30,40,12,927         20.09% 1,52,28,51,278     19.30% 1,84,92,96,520          19.91%
Profit from Operations 99,87,94,848         24.91% 1,00,12,82,411        20.57% 1,63,57,80,192         25.20% 1,98,84,79,698    25.20% 2,20,78,79,560         23.77%
Other Income 6,86,510                 0.02% 19,89,86,379            4.09% 45,60,11,134            7.03% 34,09,07,774        4.32% 44,28,47,713             4.77%
Finance Cost 24,96,54,298         6.23% 28,94,27,992            5.95% 66,21,82,384            10.20% 56,76,45,757        7.19% 64,54,06,575             6.95%
Profit before Contribution to W P P & Welfare Funds 74,98,27,060         18.70% 91,08,40,798            18.71% 1,42,96,08,942         22.02% 1,76,17,41,715     22.33% 2,00,53,20,698          21.59%
Contribution to W P P & Welfare Funds 3,57,06,050           0.89% 4,33,73,371              0.89% 6,80,76,616               1.05% 8,38,92,463          1.06% 9,54,91,462               1.03%
Profit Before Tax 71,41,21,010         17.81% 86,74,67,427            17.82% 1,36,15,32,326         20.98% 1,67,78,49,252     21.26% 1,90,98,29,236          20.56%
Income Tax Expenses 16,87,79,737         4.21% (24,27,27,120)           -4.99% 30,98,83,518            4.77% 47,93,23,910        6.07% 59,04,39,908             6.36%
Current Tax 17,37,20,430         4.33% 7,10,85,835               1.10% 20,75,49,905        2.63% 44,57,12,907             4.80%
Deferred Tax/Income 49,40,693               0.12% 24,27,27,120            4.99% 23,87,97,683            3.68% 27,17,74,005        3.44% 14,47,27,001             1.56%
Profit after Tax for the Year 54,53,41,273         13.60% 62,47,40,307            12.83% 1,05,16,48,808         16.20% 1,19,85,25,342    15.19% 1,31,93,89,328         14.20%
Other Comprehensive Income -                           -                              -                              -                         -                               
Total Comprehensive Income for the Year 54,53,41,273         13.60% 62,47,40,307            12.83% 1,05,16,48,808         16.20% 1,19,85,25,342    15.19% 1,31,93,89,328         14.20%
Earnings Per Share (EPS) / Adjusted EPS (2011) 3.61                         4.13                           5.17                            3.93                       4.33                            
Number of Shares used to compute EPS 15,11,49,296         15,11,49,296            20,34,20,202            30,46,39,050        30,46,39,050             
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The vertical analysis of Beximco’s Balance sheet shows all the components as a percentage of total assets or 
total liabilities and equity amount. The chart shows that, the basic performance indicators of the balance sheet 
like- non-current assets are seen to be highest (80.69%) in 2008 and the lowest (65.23%) in 2009. Here, all the 
non-current assets of different years have been shown as a percentage of total assets. So, Beximco had the 
highest rate of non-current assets of all assets in 2008 and the lowest rate in 2009. From current assets, we can 
see that, the highest percentage (34.77%) was in 2009 and lowest (19.31%) was in 2008. From shareholders’ 
equity, we can see that the highest rate was in 2012 (74.86%) and lowest (54.92%) in 2009. The rest of the 
percentages belonged to another element, liabilities (current and non-current). 
 
Balance sheet Vertical analysis (Beximco Pharma)
2008 2009 2010 2011 2012
ASSETS Amount % Amount % Amount % Amount % Amount %
Non-Current Assets 11,95,77,73,787   80.69% 12,97,51,95,529      65.23% 15,18,07,31,678      71.03% 15,88,48,77,780  68.96% 16,39,23,88,639       66.66%
Property, Plant and Equipment- Carrying Value 11,92,10,72,697    80.44% 12,96,65,87,178      65.19% 15,12,33,06,298       70.76% 15,74,54,92,625  68.36% 16,20,18,58,216       65.89%
Intangible Assets 57,26,525                  0.03% 5,11,26,854               0.24% 13,59,33,879        0.59% 18,70,79,147             0.76%
Investment in Shares 3,67,01,090           0.25% 28,81,826                  0.01% 62,98,526                  0.03% 34,51,276             0.01% 34,51,276                   0.01%
Current Assets 2,86,18,91,654      19.31% 6,91,67,37,893        34.77% 6,19,16,67,831         28.97% 7,14,84,62,753    31.04% 8,19,74,21,953         33.34%
Inventories 1,50,52,88,093      10.16% 1,72,29,53,284         8.66% 1,98,38,09,444         9.28% 2,29,18,44,631     9.95% 2,43,39,87,981          9.90%
Spares & Supplies 23,45,30,326         1.58% 24,20,34,855            1.22% 27,65,20,188            1.29% 32,58,81,244        1.41% 39,61,75,790             1.61%
Accounts Receivable 50,39,16,401         3.40% 69,41,11,730            3.49% 82,13,56,439            3.84% 97,82,24,317        4.25% 1,16,24,04,807          4.73%
Loans, Advances and Deposits 54,45,09,106         3.67% 69,92,04,450            3.52% 77,91,29,620            3.65% 84,03,20,705        3.65% 96,52,76,373             3.93%
Short Term Investment -                           0.00% 2,50,00,00,000         12.57% 85,94,03,704            4.02% 2,19,34,23,560     9.52% 2,68,65,98,326          10.93%
Cash and Cash Equivalents 7,36,47,728           0.50% 1,05,84,33,574         5.32% 1,47,14,48,436         6.88% 51,87,68,296        2.25% 55,29,78,676             2.25%
TOTAL ASSETS 14,81,96,65,441   100.00% 19,89,19,33,422      100.00% 21,37,23,99,509      100.00% 23,03,33,40,533  100.00% 24,58,98,10,592       100.00%
EQUITY AND LIABILITIES
Shareholders’ Equity 10,45,02,02,145   70.52% 10,88,57,06,614      54.92% 15,97,40,86,451      74.74% 17,12,81,28,177  74.36% 18,40,81,61,859       74.86%
Issued Share Capital 1,25,95,77,470      8.50% 1,51,14,92,960         7.63% 2,09,80,65,090         9.82% 2,51,76,78,100     10.93% 3,04,63,90,500          12.39%
Share Premium 1,48,97,50,000      10.05% 1,48,97,50,000         7.52% 5,26,94,74,690         24.66% 5,26,94,74,690     22.88% 5,26,94,74,690          21.43%
Excess of Issue Price over Face Value of GDRs 1,68,96,36,958      11.40% 1,68,96,36,958         8.52% 1,68,96,36,958         7.91% 1,68,96,36,958     7.34% 1,68,96,36,958          6.87%
Capital Reserve on Merger 29,49,50,950         1.99% 29,49,50,950            1.49% 29,49,50,950            1.38% 29,49,50,950        1.28% 29,49,50,950             1.20%
Revaluation Surplus 1,71,11,74,747      11.55% 1,61,73,61,714         8.16% 1,53,46,45,820         7.18% 1,46,66,02,600     6.37% 1,40,65,27,880          5.72%
Retained Earnings 4,00,51,12,020      27.03% 4,28,25,14,032         21.61% 5,08,73,12,943         23.80% 5,88,97,84,879     25.57% 6,70,11,80,881          27.25%
Non-Current Liabilities 1,76,74,31,029      11.93% 6,68,47,75,166        33.73% 2,88,51,55,826         13.50% 3,25,70,50,368    14.14% 3,11,67,03,964         12.67%
Long Term Borrowings-Net off Current Maturity (Secured) 1,44,66,00,500      9.76% 1,92,49,33,065         9.71% 1,90,21,50,733         8.90% 1,89,00,74,651     8.21% 1,46,96,21,611          5.98%
Fully Convertible,5% Dividend,Preferred share 4,10,00,00,000         20.68%
Liability for Gratuity & WPPF 27,44,19,253         1.85% 30,74,25,614            1.55% 33,58,85,792            1.57% 40,35,98,795        1.75% 49,96,22,784             2.03%
Deferred Tax Liability 4,64,11,276           0.31% 35,24,16,487            1.78% 64,71,19,301            3.03% 96,33,76,922        4.18% 1,14,74,59,569          4.67%
Current Liabilities and Provisions 2,60,20,32,267      17.56% 2,25,08,67,161        11.36% 2,51,31,57,232         11.76% 2,64,81,61,988    11.50% 3,06,49,44,769         12.46%
Short Term Borrowings 1,46,16,66,227      9.86% 1,45,13,26,354         7.32% 1,63,99,61,052         7.67% 1,64,22,16,008     7.13% 1,52,64,49,918          6.21%
Long Term Borrowings-Current Maturity 64,81,65,841         4.37% 30,88,20,056            1.56% 34,88,60,443            1.63% 36,37,44,181        1.58% 66,47,12,728             2.70%
Creditors and Other Payables 26,31,76,822         1.78% 40,98,98,122            2.07% 43,23,15,660            2.02% 52,37,98,136        2.27% 47,00,97,685             1.91%
Accrued Expenses 8,17,76,450           0.55% 7,90,94,905              0.40% 9,05,12,178               0.42% 10,15,59,917        0.44% 12,85,98,961             0.52%
Dividend Payable 31,69,568               0.02% 17,27,724                  0.01% 15,07,899                  0.01% 13,61,452             0.01% 10,20,948                   0.0042%
Income Tax Payable 14,40,77,359         0.97% 7,05,84,481              0.36% 1,54,82,294          0.07% 27,40,64,529             1.11%
Total Liabilities 4,36,94,63,296      29.48% 8,93,56,42,327        45.08% 5,39,83,13,058         25.26% 5,90,52,12,356    25.64% 6,18,16,48,733         25.14%
TOTAL EQUITY AND LIABILITIES 14,81,96,65,441   100.00% 19,82,13,48,941      100.00% 21,37,23,99,509      100.00% 23,03,33,40,533  100.00% 24,58,98,10,592       100.00%
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The chart shows the vertical analysis of GlaxoSmithKline’s Income statement, where all the components of the 
income statement has been calculated as a percentage of net sales or net revenues. The basic performance 
indicators like-Cost of sales shows that it was the lowest in 2010 which is 65.80% and highest was 75.02% in 
2008. Because of being the lowest rate in 2010 and highest in 2008 respectively, the gross profit was highest in 
2010 and lowest in 2008. By excluding all the expenses, interests and taxes, the final performance indicator 
total comprehensive income shows that, it was highest in 2010 which is 11.29%. The lowest rate can be seen in 
2012. All the other percentages are shown in the chart. 
 
 
 
 
 
Income Statement Vertical analysis (GSK)
2008 2009 2010 2011 2012
Amount % Amount % Amount % Amount % Amount %
Sales 1,88,81,05,000      100.00% 3,02,36,72,000        100.00% 3,63,20,95,000         100.00% 4,73,51,21,000    100.00% 5,55,38,12,000         100.00%
Cost of Sales 1,41,64,32,000      75.02% 2,07,93,89,000        68.77% 2,38,97,42,000         65.80% 3,38,66,70,000    71.52% 3,96,49,00,000         71.39%
Gross Profit 47,16,73,000         24.98% 94,42,83,000            31.23% 1,24,23,53,000         34.20% 1,34,84,51,000    28.48% 1,58,89,12,000         28.61%
Operating Expenses:
Selling Expenses 17,49,35,000         9.27% 39,63,26,000            13.11% 55,78,08,000            15.36% 74,81,74,000        15.80% 1,06,59,00,000          19.19%
Distribution expenses 58,79,000               0.31% 31,39,000                  0.10% 73,72,000                  0.20% 82,61,000             0.17% 2,13,65,000               0.38%
Administrative expenses 8,26,67,000           4.38% 11,98,89,000            3.97% 14,57,17,000            4.01% 18,72,16,000        3.95% 14,19,04,000             2.56%
Other income 44,36,000               0.23% 69,30,000                  0.23% 41,41,000                  0.11% 1,21,26,000          0.26% 1,59,27,000               0.29%
Total 25,90,45,000         13.72% 51,24,24,000            16.95% 70,67,56,000            19.46% 93,15,25,000        19.67% 1,21,32,42,000         21.85%
Profit from operations 21,26,28,000         11.26% 43,18,59,000            14.28% 53,55,97,000            14.75% 41,69,26,000        8.80% 37,56,70,000             6.76%
Finance Income 4,08,000                 0.02% 77,94,000                  0.26% 1,79,83,000               0.50% 5,21,63,000          1.10% 5,51,92,000               0.99%
Finance costs 84,27,000               0.45% 8,31,000                    0.03% 8,20,000                    0.02% 37,59,000             0.08%
Profit before charging WPPF 20,46,09,000         10.84% 43,88,22,000            14.51% 55,27,60,000            15.22% 46,53,30,000        9.83% 43,08,62,000             7.76%
Allocation for WPPF 2,15,23,000               0.39%
Profit before taxation 20,46,09,000         10.84% 43,88,22,000            14.51% 55,27,60,000            15.22% 46,53,30,000        9.83% 40,93,39,000             7.37%
Income tax expenses 6,16,60,000           3.27% 11,50,35,000            3.80% 14,25,83,000            3.93% 18,32,62,000        3.87% 16,53,72,000             2.98%
Profit for the year 14,29,49,000         7.57% 32,37,87,000            10.71% 41,01,77,000            11.29% 28,20,68,000        5.96% 24,39,67,000             4.39%
Other comprehensive income
Total comprehensive income for the year 14,29,49,000         7.57% 32,37,87,000            10.71% 41,01,77,000            11.29% 28,20,68,000        5.96% 24,39,67,000             4.39%
EPS 11.87                      26.88                         34.05                          23.41                     20.00                          
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The vertical analysis of GlaxoSmithKline’s Balance sheet shows all the components as a percentage of total 
assets or total liabilities and equity amount. The chart shows that, the basic performance indicators of the 
balance sheet like- non-current assets are seen to be highest (25.24%) in 2008 and the lowest (16.25%) in 
2012. Here, all the non-current assets of different years have been shown as a percentage of total assets. So, 
Beximco had the highest rate of non-current assets of all assets in 2008 and the lowest rate in 2009. From 
current assets, we can see that, the highest percentage (83.75%) was in 2012 and lowest (74.76%) was in 2008. 
From shareholders’ equity, we can see that the highest rate was in 2009 (68.39%) and lowest (48.48%) in 
2012. The rest of the percentages belonged to another element, liabilities (current and non-current). 
 
 
 
 
 
2008 2009 2010 2011 2012
Assets Amount % Amount % Amount % Amount % Amount %
Non-current assets 34,38,90,000         25.24% 36,72,18,000            21.58% 39,01,07,000            17.62% 48,06,62,000        18.48% 49,78,30,000             16.25%
Property,plant and equipment 32,64,67,000         23.96% 34,88,15,000            20.50% 36,81,02,000            16.62% 48,06,62,000        18.48% 49,78,30,000             16.25%
Deferred tax asset 1,74,23,000           1.28% 1,84,03,000              1.08% 2,20,05,000               0.99%
Current asstes 1,01,84,58,000      74.76% 1,33,42,84,000        78.42% 1,82,41,78,000         82.38% 2,12,07,92,000    81.52% 2,56,63,76,000         83.75%
Inventories 59,62,05,000         43.76% 61,05,25,000            35.88% 69,52,31,000            31.40% 1,13,88,44,000     43.78% 1,05,95,44,000          34.58%
Trade and other receivables 42,03,16,000         30.85% 40,94,64,000            24.06% 46,29,04,000            20.91% 21,13,64,000        8.12% 48,73,98,000             15.91%
Cash and cash equivalents 19,37,000               0.14% 31,42,95,000            18.47% 66,60,43,000            30.08% 77,05,84,000        29.62% 1,01,94,34,000          33.27%
Total assets 1,36,23,48,000      100.00% 1,70,15,02,000        100.00% 2,21,42,85,000         100.00% 2,60,14,54,000    100.00% 3,06,42,06,000         100.00%
Equity and Liabilities
Share capital 12,04,65,000         8.84% 12,04,65,000            7.08% 12,04,65,000            5.44% 12,04,65,000        4.63% 12,04,65,000             3.93%
Retained earnings 72,70,03,000         53.36% 97,85,11,000            57.51% 1,19,60,41,000         54.01% 1,23,71,80,000     47.56% 1,30,04,50,000          42.44%
Revaluation reserves 5,94,79,000          2.29% 5,94,79,000               1.94%
General reserves 50,00,000               0.37% 50,00,000                  0.29% 50,00,000                  0.23% 50,00,000             0.19% 50,00,000                   0.16%
Capital reserves 5,97,42,000           4.39% 5,97,42,000              3.51% 5,96,45,000               2.69% 1,66,000                0.01% 1,66,000                     0.01%
Total equity 91,22,10,000         66.96% 1,16,37,18,000        68.39% 1,38,11,51,000         62.37% 1,42,22,90,000    54.67% 1,48,55,60,000         48.48%
Liabilities
Non-current liabilities
Deferred tax liability 3,60,28,000           2.64% 3,67,69,000              2.16% 4,60,79,000               2.08% 3,59,01,000          1.38% 3,85,12,000               1.26%
Retirement benefit obligations 6,88,11,000           5.05% 6,69,19,000              3.93% 8,00,20,000               3.61% 8,21,39,000          3.16% 8,38,74,000               2.74%
Obligation under finance lease 13,00,000               0.10% 49,39,000                  0.29% 36,39,000                  0.16% 2,69,38,000          1.04% 2,24,03,000               0.73%
Total non-current Liabilities 10,61,39,000         7.79% 10,86,27,000            6.38% 12,97,38,000            5.86% 14,49,78,000        5.57% 14,47,89,000             4.73%
Current Liabilities
Trade and other payables 32,84,95,000         24.11% 36,14,63,000            21.24% 63,28,79,000            28.58% 99,50,94,000        38.25% 1,36,94,68,000          44.69%
Current tax liabilities 1,31,67,000           0.97% 6,65,21,000              3.91% 6,92,19,000               3.13% 3,24,69,000          1.25% 5,66,54,000               1.85%
Obligation under finance lease 23,37,000               0.17% 11,73,000                  0.07% 12,98,000                  0.06% 66,23,000             0.25% 77,35,000                   0.25%
Total current liabilities 34,39,99,000         25.25% 42,91,57,000            25.22% 70,33,96,000            31.77% 1,03,41,86,000    39.75% 1,43,38,57,000         46.79%
Total liabilities 45,01,38,000         33.04% 53,77,84,000            31.61% 83,31,34,000            37.63% 1,17,91,64,000    45.33% 1,57,86,46,000         51.52%
Total Equity and Liabilities 1,36,23,48,000      100.00% 1,70,15,02,000        100.00% 2,21,42,85,000         100.00% 2,60,14,54,000    100.00% 3,06,42,06,000         100.00%
Balance Sheet Vertical analysis (GSK)
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2.
 
The chart here shows the growth rate in different years compared to the previous years for each of the items. In 
Square’s income statement we can see that, all the values are positive except financial expenses and other 
income. It is good sign for Square that their financial expenses went down which helped them to increase their 
income from 2008 to 2012. 
 
 
 
 Horizontal analysis: 
Horizontal analysis of financial statements involve comparison of a financial ratio, a benchmark, or a line item 
over a number of accounting periods. This method of analysis is also known as trend analysis. Horizontal 
analysis allows the assessment of relative changes in different items over time. Here, the horizontal analysis 
among GSK, Square and Beximco is done to understand each of the company’s growth rates in each element 
of Income statements and Balance sheets.  
Income Statement Horizontal analysis (Square Pharma)
2008 2009 2010 2011 2012 % change in % change in % change in % change in
Amount Amount Amount Amount Amount 2009 2010 2011 2012
Net sales 9,82,07,96,568             11,46,25,78,410      13,47,14,24,469   16,05,44,25,243      17,95,94,89,496   16.72% 17.53% 19.17% 11.87%
COGS 5,67,25,65,973             6,56,12,88,485         7,70,36,61,010      9,16,72,53,620        10,22,34,78,073   15.67% 17.41% 19.00% 11.52%
Gross Profit 4,14,82,30,595             4,90,12,89,925         5,76,77,63,459      6,88,71,71,623        7,73,60,11,423     18.15% 17.68% 19.41% 12.32%
Operating expenses 2,17,69,29,331             2,52,05,32,046         3,01,61,58,062      3,56,60,24,910        3,88,32,00,849     15.78% 19.66% 18.23% 8.89%
Selling and Distribution expenses 1,31,93,62,317             1,68,72,10,447         2,12,11,63,004      2,43,04,66,795        2,82,05,82,797     27.88% 25.72% 14.58% 16.05%
Administrative expenses 46,04,31,051                52,44,60,492            62,61,45,987         70,19,77,079           73,73,37,036        13.91% 19.39% 12.11% 5.04%
Financial expenses 39,71,35,963                30,88,61,107            26,88,49,071         43,35,81,036           32,52,81,016        -22.23% -12.95% 61.27% -24.98%
Profit from operations 1,97,13,01,264             2,38,07,57,879         2,75,16,05,397      3,32,11,46,713        3,85,28,10,574     20.77% 15.58% 20.70% 16.01%
Other income 66,55,20,915                58,55,64,826            83,38,84,528         85,67,39,329           85,22,89,241        -12.01% 42.41% 2.74% -0.52%
Profit before WPPF 2,63,68,22,179             2,96,63,22,705         3,58,54,89,925      4,17,78,86,042        4,70,50,99,815     12.50% 20.87% 16.52% 12.62%
Allocations for WPPF 12,55,62,961                14,12,53,462            17,07,37,615         19,89,46,954           22,40,52,372        12.50% 20.87% 16.52% 12.62%
Profit before Tax 2,51,12,59,218             2,82,50,69,243         3,41,47,52,310      3,97,89,39,088        4,48,10,47,443     12.50% 20.87% 16.52% 12.62%
Provision for Income Tax 59,26,44,226                68,84,99,602            80,55,75,198         95,89,06,349           1,06,77,70,353     16.17% 17.00% 19.03% 11.35%
Provision for Deferred Income Tax 2,85,62,063                   4,86,97,850               7,71,22,562           12,23,22,098           7,18,52,307           70.50% 58.37% 58.61% -41.26%
Profit after Tax 1,89,00,52,929             2,08,78,71,791         2,53,20,54,550      2,89,77,10,641        3,34,14,24,783     10.47% 21.27% 14.44% 15.31%
Other comprehensive Income: -                                  -                              
Gain on marketable securities -                                  -                              9,24,83,089           13,99,86,324           10,14,75,954        51.36% -27.51%
Total comprehensive Income 1,89,00,52,929             2,08,78,71,791         2,62,45,37,639      3,03,76,96,965        3,23,99,48,829     10.47% 25.70% 15.74% 6.66%
EPS 125.25                            138.36                       129.07                    11.00                         9.01                        
Number of shares used to compute EPS 1,50,90,300                   1,50,90,300               1,96,17,390           26,48,34,760           37,07,68,664        
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From the horizontal analysis of the balance sheet of Square, we can see that, all the values in percentage 
change are positive except some values in long term investment, current assets, inventories, short term loans 
and some liabilities. Negative value indicates that these items have decreased than previous years and the 
positive values say that each value had an increase compared to the previous year. The amount here shows the 
growth percentage which says by what percentage an item had an increase or decrease. Some items had no 
change in their values, so it indicates a 0% change. Some core performance indicators of balance sheet like- 
non-current asset shows, it had the highest percentage of increase in 2011, but again decreased in 2012, current 
assets are seen to have a slightly decreasing rate, shareholders’ equity had a positive change over the five 
years, liabilities are also seen to be following a decreasing trend which is good as the company is gradually 
trying to decrease their liability amount. 
 
Balance Sheet Horizontal analysis (Square Pharma)
2008 2009 2010 2011 2012 % change in % change in % change in % change in
ASSETS: Amount Amount Amount Amount Amount 2009 2010 2011 2012
Non-Current Assets: 9,40,77,30,001             10,25,51,89,084      12,42,21,95,814   14,70,82,77,754      17,45,09,47,962   9.01% 21.13% 18.40% 18.65%
Property, Plant and Equipment-Carrying Value 4,89,96,79,832             5,63,07,91,822         6,98,15,59,781      8,76,78,27,062        9,32,21,86,497     14.92% 23.99% 25.59% 6.32%
Capital Work-in-Progress -                                  63,43,47,093            88,75,84,197         1,27,43,90,572        3,71,83,26,254     39.92% 43.58% 191.77%
Investment - Long Term (at Cost) 4,50,80,50,169             3,99,00,50,169         4,03,17,51,281      3,97,10,22,723        3,82,11,21,331     -11.49% 1.05% -1.51% -3.77%
Investment in Marketable Securities (Fair Value) 52,13,00,555         69,50,37,397           58,93,13,880        33.33% -15.21%
Current Assets: 3,84,35,12,855             4,77,43,11,194         7,02,22,13,840      6,74,55,07,008        5,99,66,97,544     24.22% 47.08% -3.94% -11.10%
Inventories 2,09,87,55,231             2,20,70,78,082         2,54,16,88,329      2,68,78,18,472        2,50,36,83,240     5.16% 15.16% 5.75% -6.85%
Trade Debtors 47,75,62,002                50,82,49,174            77,24,21,345         80,83,11,714           80,09,74,912        6.43% 51.98% 4.65% -0.91%
Advances,Deposits and Prepayments 26,03,30,162                35,82,50,076            52,39,91,079         57,71,56,445           65,03,80,369        37.61% 46.26% 10.15% 12.69%
Investment in marketable securities(at cost) 2,02,50,000                   22,12,69,226            
Short Term Loan 69,31,57,720                1,22,07,36,941         2,81,38,11,332      2,08,53,00,110        1,10,92,51,152     76.11% 130.50% -25.89% -46.81%
Cash and Cash Equivalents 29,34,57,740                25,87,27,695            37,03,01,755         58,69,20,267           93,24,07,871        -11.83% 43.12% 58.50% 58.86%
TOTAL ASSETS 13,25,12,42,856           15,02,95,00,278      19,44,44,09,654   21,45,37,84,762      23,44,76,45,506   13.42% 29.37% 10.33% 9.29%
SHAREHOLDERS' EQUITY AND LIABILITIES:
Shareholders' Equity: 9,94,93,97,634             11,55,43,79,825      13,81,77,05,990   16,26,68,84,255      18,84,47,46,184   16.13% 19.59% 17.72% 15.85%
Share Capital 1,20,72,24,000             1,50,90,30,000         1,96,17,39,000      2,64,83,47,600        3,70,76,86,640     25.00% 30.00% 35.00% 40.00%
Share Premium 2,03,54,65,000             2,03,54,65,000         2,03,54,65,000      2,03,54,65,000        2,03,54,65,000     0.00% 0.00% 0.00% 0.00%
General Reserve 10,58,78,200                10,58,78,200            10,58,75,200         10,58,78,200           10,58,78,200        0.00% 0.00% 0.00% 0.00%
Tax Holiday Reserve 1,10,19,35,237             1,10,19,35,237         1,10,19,35,237      -                             -                          0.00% 0.00% -100.00%
Gain on Marketable Securities (Unrealized) 25,94,35,115         39,94,21,439           29,79,45,485        53.96% -25.41%
Retained Earnings 5,49,88,95,197             6,80,20,71,388         8,35,32,56,438      11,07,77,72,016      12,69,77,70,859   23.70% 22.80% 32.62% 14.62%
Non-Current Liabilities: 66,09,76,668                1,25,83,76,052         95,85,11,238         93,39,65,662           81,04,61,067        90.38% -23.83% -2.56% -13.22%
Long Term Loans - Secured 44,97,57,608                1,03,26,33,110         65,56,45,734         50,87,78,060           31,34,21,158        129.60% -36.51% -22.40% -38.40%
Deferred Tax Liability 21,12,19,060                22,57,42,942            30,28,65,504         42,51,87,602           49,70,39,909        6.88% 34.16% 40.39% 16.90%
Current Liabilities: 2,64,08,68,554             2,21,67,44,401         4,66,81,89,426      4,25,29,34,845        3,79,24,38,255     -16.06% 110.59% -8.90% -10.83%
Short Term Bank Loans 1,53,43,45,782             73,64,43,848            2,62,74,83,864      2,01,65,51,125        1,11,26,94,131     -52.00% 256.78% -23.25% -44.82%
Long Term Loans - Current Portion 29,55,90,601                46,20,90,211            47,81,99,933         47,71,41,480           51,15,04,034        56.33% 3.49% -0.22% 7.20%
Trade Creditors 12,42,22,699                39,47,15,915            73,33,69,218         87,54,31,555           1,08,60,97,881     217.75% 85.80% 19.37% 24.06%
Liabilities for Expenses 6,95,73,702                   5,64,63,570               7,94,99,584           9,53,61,435              10,96,04,834        -18.84% 40.80% 19.95% 14.94%
Liabilities for Other Finance 61,71,35,770                56,70,30,857            74,96,36,827         78,84,49,250           97,25,37,375        -8.12% 32.20% 5.18% 23.35%
Total Liabilities: 3,30,18,45,222             3,47,51,20,453         5,62,67,00,664      5,18,69,00,507        4,60,28,99,322     5.25% 61.91% -7.82% -11.26%
TOTAL SHAREHOLDERS' EQUITY AND LIABILITIES 13,25,12,42,856           15,02,95,00,278      19,44,44,06,654   21,45,37,84,762      23,44,76,45,506   13.42% 29.37% 10.33% 9.29%
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The horizontal analysis of Beximco’s income statement is showing the growth rate change throughout the five 
years period of time. Here, all the values are seen to have increased in a positive rate except some values in 
other income, finance costs, income tax expenses etc. Expenses which have a decreasing growth rate is a good 
sign for the company as it indicates that they have succeeded to decrease their expenses throughout the period. 
The basic performance indicator in an income statement like- net sales shows that the highest increase was in 
2010 and lowest in 2012. However, it is always having a positive increase which says their sales increased day 
by day. The increase rate of COGS decreased to some extents and finally the net income is seen to be 
increasing at a decreasing rate. 
 
 
 
 
Income Statement Horizontal analysis (Beximco Pharma)
2008 2009 2010 2011 2012 % change in % change in % change in % change in
Amount Amount Amount Amount Amount 2009 2010 2011 2012
Net Sales Revenue 4,01,01,67,059             4,86,82,54,915         6,49,08,47,353      7,89,02,41,843        9,28,91,15,284     21.40% 33.33% 21.56% 17.73%
Cost of Goods Sold 2,00,28,71,181             2,56,62,06,626         3,31,76,40,254      4,10,37,09,021        4,89,97,13,857     28.13% 29.28% 23.69% 19.40%
Gross Profit 2,00,72,95,878             2,30,20,48,289         3,17,32,07,099      3,78,65,32,822        4,38,94,01,427     14.68% 37.84% 19.33% 15.92%
Operating Expenses 1,00,85,01,030             1,30,07,65,878         1,53,74,26,907      1,79,80,53,124        2,18,15,21,867     28.98% 18.19% 16.95% 21.33%
Administrative Expenses 15,34,64,243                21,51,92,547            23,34,13,980         27,52,01,846           33,22,25,347        40.22% 8.47% 17.90% 20.72%
Selling, Marketing and Distribution Expenses 85,50,36,787                1,08,55,73,331         1,30,40,12,927      1,52,28,51,278        1,84,92,96,520     26.96% 20.12% 16.78% 21.44%
Profit from Operations 99,87,94,848                1,00,12,82,411         1,63,57,80,192      1,98,84,79,698        2,20,78,79,560     0.25% 63.37% 21.56% 11.03%
Other Income 6,86,510                        19,89,86,379            45,60,11,134         34,09,07,774           44,28,47,713        28885.21% 129.17% -25.24% 29.90%
Finance Cost 24,96,54,298                28,94,27,992            66,21,82,384         56,76,45,757           64,54,06,575        15.93% 128.79% -14.28% 13.70%
Profit before Contribution to W P P & Welfare Funds 74,98,27,060                91,08,40,798            1,42,96,08,942      1,76,17,41,715        2,00,53,20,698     21.47% 56.95% 23.23% 13.83%
Contribution to W P P & Welfare Funds 3,57,06,050                   4,33,73,371               6,80,76,616           8,38,92,463              9,54,91,462           21.47% 56.95% 23.23% 13.83%
Profit Before Tax 71,41,21,010                86,74,67,427            1,36,15,32,326      1,67,78,49,252        1,90,98,29,236     21.47% 56.95% 23.23% 13.83%
Income Tax Expenses 16,87,79,737                (24,27,27,120)           30,98,83,518         47,93,23,910           59,04,39,908        -243.81% -227.67% 54.68% 23.18%
Current Tax 17,37,20,430                -                              7,10,85,835           20,75,49,905           44,57,12,907        -100.00% 191.97% 114.75%
Deferred Tax/Income 49,40,693                      24,27,27,120            23,87,97,683         27,17,74,005           14,47,27,001        4812.82% -1.62% 13.81% -46.75%
Profit after Tax for the Year 54,53,41,273                62,47,40,307            1,05,16,48,808      1,19,85,25,342        1,31,93,89,328     14.56% 68.33% 13.97% 10.08%
Other Comprehensive Income -                                  -                              -                           -                             -                          
Total Comprehensive Income for the Year 54,53,41,273                62,47,40,307            1,05,16,48,808      1,19,85,25,342        1,31,93,89,328     14.56% 68.33% 13.97% 10.08%
Earnings Per Share (EPS) / Adjusted EPS (2011) 3.61                                4.13                            5.17                         3.93                           4.33                        
Number of Shares used to compute EPS 15,11,49,296                15,11,49,296            20,34,20,202         30,46,39,050           30,46,39,050        
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From the horizontal analysis of the balance sheet of Beximco, we can see that, some of the values are having a 
negative change throughout the years.  Negative value indicates that these items had decreased than previous 
years and the positive values say that each value had an increase compared to the previous year. The amount 
here shows the growth percentage which says by what percentage an item had an increase or decrease. Some 
items had no change in their values, so it indicates a 0% change. Some core performance indicators of balance 
sheet like- non-current asset shows, it had the highest percentage of increase in 2010, but again decreased in 
2011 and 2012, current assets are seen to be increasing at a decreasing rate, shareholders’ equity had a positive 
change over the five years, liabilities are also seen to be following a decreasing trend which is good as the 
company is gradually trying to decrease their liability amount. 
 
 
 
2008 2009 2010 2011 2012 % change in % change in % change in % change in
ASSETS Amount Amount Amount Amount Amount 2009 2010 2011 2012
Non-Current Assets 11,95,77,73,787           12,97,51,95,529      15,18,07,31,678   15,88,48,77,780      16,39,23,88,639   8.51% 17.00% 4.64% 3.19%
Property, Plant and Equipment- Carrying Value 11,92,10,72,697           12,96,65,87,178       15,12,33,06,298    15,74,54,92,625      16,20,18,58,216   8.77% 16.63% 4.11% 2.90%
Intangible Assets -                                  57,26,525                  5,11,26,854           13,59,33,879           18,70,79,147        792.81% 165.88% 37.63%
Investment in Shares 3,67,01,090                  28,81,826                  62,98,526               34,51,276                 34,51,276              -92.15% 118.56% -45.21% 0.00%
Current Assets 2,86,18,91,654             6,91,67,37,893         6,19,16,67,831      7,14,84,62,753        8,19,74,21,953     141.68% -10.48% 15.45% 14.67%
Inventories 1,50,52,88,093             1,72,29,53,284         1,98,38,09,444      2,29,18,44,631        2,43,39,87,981     14.46% 15.14% 15.53% 6.20%
Spares & Supplies 23,45,30,326                24,20,34,855            27,65,20,188         32,58,81,244           39,61,75,790        3.20% 14.25% 17.85% 21.57%
Accounts Receivable 50,39,16,401                69,41,11,730            82,13,56,439         97,82,24,317           1,16,24,04,807     37.74% 18.33% 19.10% 18.83%
Loans, Advances and Deposits 54,45,09,106                69,92,04,450            77,91,29,620         84,03,20,705           96,52,76,373        28.41% 11.43% 7.85% 14.87%
Short Term Investment -                                  2,50,00,00,000         85,94,03,704         2,19,34,23,560        2,68,65,98,326     -65.62% 155.23% 22.48%
Cash and Cash Equivalents 7,36,47,728                   1,05,84,33,574         1,47,14,48,436      51,87,68,296           55,29,78,676        1337.16% 39.02% -64.74% 6.59%
TOTAL ASSETS 14,81,96,65,441           19,89,19,33,422      21,37,23,99,509   23,03,33,40,533      24,58,98,10,592   34.23% 7.44% 7.77% 6.76%
Shareholders’ Equity 10,45,02,02,145           10,88,57,06,614      15,97,40,86,451   17,12,81,28,177      18,40,81,61,859   4.17% 46.74% 7.22% 7.47%
Issued Share Capital 1,25,95,77,470             1,51,14,92,960         2,09,80,65,090      2,51,76,78,100        3,04,63,90,500     20.00% 38.81% 20.00% 21.00%
Share Premium 1,48,97,50,000             1,48,97,50,000         5,26,94,74,690      5,26,94,74,690        5,26,94,74,690     0.00% 253.72% 0.00% 0.00%
Excess of Issue Price over Face Value of GDRs 1,68,96,36,958             1,68,96,36,958         1,68,96,36,958      1,68,96,36,958        1,68,96,36,958     0.00% 0.00% 0.00% 0.00%
Capital Reserve on Merger 29,49,50,950                29,49,50,950            29,49,50,950         29,49,50,950           29,49,50,950        0.00% 0.00% 0.00% 0.00%
Revaluation Surplus 1,71,11,74,747             1,61,73,61,714         1,53,46,45,820      1,46,66,02,600        1,40,65,27,880     -5.48% -5.11% -4.43% -4.10%
Retained Earnings 4,00,51,12,020             4,28,25,14,032         5,08,73,12,943      5,88,97,84,879        6,70,11,80,881     6.93% 18.79% 15.77% 13.78%
Non-Current Liabilities 1,76,74,31,029             6,68,47,75,166         2,88,51,55,826      3,25,70,50,368        3,11,67,03,964     278.22% -56.84% 12.89% -4.31%
Long Term Borrowings-Net off Current Maturity (Secured) 1,44,66,00,500             1,92,49,33,065         1,90,21,50,733      1,89,00,74,651        1,46,96,21,611     33.07% -1.18% -0.63% -22.25%
Fully Convertible,5% Dividend,Preferred share 4,10,00,00,000         
Liability for Gratuity & WPPF 27,44,19,253                30,74,25,614            33,58,85,792         40,35,98,795           49,96,22,784        12.03% 9.26% 20.16% 23.79%
Deferred Tax Liability 4,64,11,276                   35,24,16,487            64,71,19,301         96,33,76,922           1,14,74,59,569     659.33% 83.62% 48.87% 19.11%
Current Liabilities and Provisions 2,60,20,32,267             2,25,08,67,161         2,51,31,57,232      2,64,81,61,988        3,06,49,44,769     -13.50% 11.65% 5.37% 15.74%
Short Term Borrowings 1,46,16,66,227             1,45,13,26,354         1,63,99,61,052      1,64,22,16,008        1,52,64,49,918     -0.71% 13.00% 0.14% -7.05%
Long Term Borrowings-Current Maturity 64,81,65,841                30,88,20,056            34,88,60,443         36,37,44,181           66,47,12,728        -52.35% 12.97% 4.27% 82.74%
Creditors and Other Payables 26,31,76,822                40,98,98,122            43,23,15,660         52,37,98,136           47,00,97,685        55.75% 5.47% 21.16% -10.25%
Accrued Expenses 8,17,76,450                   7,90,94,905               9,05,12,178           10,15,59,917           12,85,98,961        -3.28% 14.43% 12.21% 26.62%
Dividend Payable 31,69,568                      17,27,724                  15,07,899               13,61,452                 10,20,948              -45.49% -12.72% -9.71% -25.01%
Income Tax Payable 14,40,77,359                7,05,84,481               -                           1,54,82,294              27,40,64,529        -51.01% -100.00% 1670.18%
Total Liabilities 4,36,94,63,296             8,93,56,42,327         5,39,83,13,058      5,90,52,12,356        6,18,16,48,733     104.50% -39.59% 9.39% 4.68%
TOTAL EQUITY AND LIABILITIES 14,81,96,65,441           19,82,13,48,941      21,37,23,99,509   23,03,33,40,533      24,58,98,10,592   33.75% 7.83% 7.77% 6.76%
Balance Sheet Horizontal analysis (Beximco Pharma)
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The horizontal analysis of GSK’s income statement is showing the growth rate change throughout the five 
years period of time. Here, all the values are seen to have increased in a positive rate except some values in 
other income, finance costs, profit for the year etc. Expenses which have a decreasing growth rate is a good 
sign for the company as it indicates that they have succeeded to decrease their expenses throughout the period. 
The basic performance indicator in an income statement like- net sales shows that the highest increase was in 
2009 and lowest in 2012. However, it is always having a positive increase which says their sales increased day 
by day. The increase rate of COGS is fluctuating and finally the net income is seen to be negative in last two 
years which is not a very good sign as it indicates that their income is decreasing. 
 
 
 
2008 2009 2010 2011 2012 % change in % change in % change in % change in
Amount Amount Amount Amount Amount 2009 2010 2011 2012
Sales 1,88,81,05,000             3,02,36,72,000         3,63,20,95,000      4,73,51,21,000        5,55,38,12,000     60.14% 20.12% 30.37% 17.29%
Cost of Sales 1,41,64,32,000             2,07,93,89,000         2,38,97,42,000      3,38,66,70,000        3,96,49,00,000     46.80% 14.93% 41.72% 17.07%
Gross Profit 47,16,73,000                94,42,83,000            1,24,23,53,000      1,34,84,51,000        1,58,89,12,000     100.20% 31.57% 8.54% 17.83%
Operating Expenses:
Selling Expenses 17,49,35,000                39,63,26,000            55,78,08,000         74,81,74,000           1,06,59,00,000     126.56% 40.74% 34.13% 42.47%
Distribution expenses 58,79,000                      31,39,000                  73,72,000               82,61,000                 2,13,65,000           -46.61% 134.85% 12.06% 158.62%
Administrative expenses 8,26,67,000                   11,98,89,000            14,57,17,000         18,72,16,000           14,19,04,000        45.03% 21.54% 28.48% -24.20%
Other income 44,36,000                      69,30,000                  41,41,000               1,21,26,000              1,59,27,000           56.22% -40.25% 192.83% 31.35%
Total 25,90,45,000                51,24,24,000            70,67,56,000         93,15,25,000           1,21,32,42,000     97.81% 37.92% 31.80% 30.24%
Profit from operations 21,26,28,000                43,18,59,000            53,55,97,000         41,69,26,000           37,56,70,000        103.11% 24.02% -22.16% -9.90%
Finance Income 4,08,000                        77,94,000                  1,79,83,000           5,21,63,000              5,51,92,000           1810.29% 130.73% 190.07% 5.81%
Finance costs 84,27,000                      8,31,000                    8,20,000                 37,59,000                 -                          -90.14% -1.32% 358.41% -100.00%
Profit before charging WPPF 20,46,09,000                43,88,22,000            55,27,60,000         46,53,30,000           43,08,62,000        114.47% 25.96% -15.82% -7.41%
Allocation for WPPF -                                  -                              -                           -                             2,15,23,000           
Profit before taxation 20,46,09,000                43,88,22,000            55,27,60,000         46,53,30,000           40,93,39,000        114.47% 25.96% -15.82% -12.03%
Income tax expenses 6,16,60,000                   11,50,35,000            14,25,83,000         18,32,62,000           16,53,72,000        86.56% 23.95% 28.53% -9.76%
Profit for the year 14,29,49,000                32,37,87,000            41,01,77,000         28,20,68,000           24,39,67,000        126.51% 26.68% -31.23% -13.51%
Other comprehensive income -                                  -                              -                           -                             -                          
Total comprehensive income for the year 14,29,49,000                32,37,87,000            41,01,77,000         28,20,68,000           24,39,67,000        126.51% 26.68% -31.23% -13.51%
EPS 11.87                              26.88                          34.05                      23.41                         20.25                      
Income Statement Horizontal analysis (GSK)
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From the horizontal analysis of the balance sheet of GSK, we can see that, some of the values are having a 
negative change throughout the years.  Negative value indicates that these items had decreased than previous 
years and the positive values say that each value had an increase compared to the previous year. The amount 
here shows the growth percentage which says by what percentage an item had an increase or decrease. Some 
items had no change in their values, so it indicates a 0% change. Some core performance indicators of balance 
sheet like- non-current asset shows, it had the highest percentage of increase in 2011, but again decreased in 
2012, current assets are seen to be fluctuating, shareholders’ equity had a positive change over the five years, 
liabilities are also seen to be following a decreasing trend which is good as the company is gradually trying to 
decrease their liability amount. 
 
 
2008 2009 2010 2011 2012 % change in % change in % change in % change in
Assets Amount Amount Amount Amount Amount 2009 2010 2011 2012
Non-current assets 34,38,90,000                36,72,18,000            39,01,07,000         48,06,62,000           49,78,30,000        6.78% 6.23% 23.21% 3.57%
Property,plant and equipment 32,64,67,000                34,88,15,000            36,81,02,000         48,06,62,000           49,78,30,000        6.85% 5.53% 30.58% 3.57%
Deferred tax asset 1,74,23,000                   1,84,03,000               2,20,05,000           -                             -                          5.62% 19.57% -100.00%
Current asstes 1,01,84,58,000             1,33,42,84,000         1,82,41,78,000      2,12,07,92,000        2,56,63,76,000     31.01% 36.72% 16.26% 21.01%
Inventories 59,62,05,000                61,05,25,000            69,52,31,000         1,13,88,44,000        1,05,95,44,000     2.40% 13.87% 63.81% -6.96%
Trade and other receivables 42,03,16,000                40,94,64,000            46,29,04,000         21,13,64,000           48,73,98,000        -2.58% 13.05% -54.34% 130.60%
Cash and cash equivalents 19,37,000                      31,42,95,000            66,60,43,000         77,05,84,000           1,01,94,34,000     16125.86% 111.92% 15.70% 32.29%
Total assets 1,36,23,48,000             1,70,15,02,000         2,21,42,85,000      2,60,14,54,000        3,06,42,06,000     24.89% 30.14% 17.49% 17.79%
Equity and Liabilities
Share capital 12,04,65,000                12,04,65,000            12,04,65,000         12,04,65,000           12,04,65,000        0.00% 0.00% 0.00% 0.00%
Retained earnings 72,70,03,000                97,85,11,000            1,19,60,41,000      1,23,71,80,000        1,30,04,50,000     34.60% 22.23% 3.44% 5.11%
Revaluation reserves -                                  -                              -                           5,94,79,000              5,94,79,000           0.00%
General reserves 50,00,000                      50,00,000                  50,00,000               50,00,000                 50,00,000              0.00% 0.00% 0.00% 0.00%
Capital reserves 5,97,42,000                   5,97,42,000               5,96,45,000           1,66,000                   1,66,000                0.00% -0.16% -99.72% 0.00%
Total equity 91,22,10,000                1,16,37,18,000         1,38,11,51,000      1,42,22,90,000        1,48,55,60,000     27.57% 18.68% 2.98% 4.45%
Liabilities
Non-current liabilities
Deferred tax liability 3,60,28,000                   3,67,69,000               4,60,79,000           3,59,01,000              3,85,12,000           2.06% 25.32% -22.09% 7.27%
Retirement benefit obligations 6,88,11,000                   6,69,19,000               8,00,20,000           8,21,39,000              8,38,74,000           -2.75% 19.58% 2.65% 2.11%
Obligation under finance lease 13,00,000                      49,39,000                  36,39,000               2,69,38,000              2,24,03,000           279.92% -26.32% 640.26% -16.83%
Total non-current Liabilities 10,61,39,000                10,86,27,000            12,97,38,000         14,49,78,000           14,47,89,000        2.34% 19.43% 11.75% -0.13%
Current Liabilities
Trade and other payables 32,84,95,000                36,14,63,000            63,28,79,000         99,50,94,000           1,36,94,68,000     10.04% 75.09% 57.23% 37.62%
Current tax liabilities 1,31,67,000                   6,65,21,000               6,92,19,000           3,24,69,000              5,66,54,000           405.21% 4.06% -53.09% 74.49%
Obligation under finance lease 23,37,000                      11,73,000                  12,98,000               66,23,000                 77,35,000              -49.81% 10.66% 410.25% 16.79%
Total current liabilities 34,39,99,000                42,91,57,000            70,33,96,000         1,03,41,86,000        1,43,38,57,000     24.76% 63.90% 47.03% 38.65%
Total liabilities 45,01,38,000                53,77,84,000            83,31,34,000         1,17,91,64,000        1,57,86,46,000     19.47% 54.92% 41.53% 33.88%
Total Equity and Liabilities 1,36,23,48,000             1,70,15,02,000         2,21,42,85,000      2,60,14,54,000        3,06,42,06,000     24.89% 30.14% 17.49% 17.79%
Balance Sheet Horizontal analysis (GSK)
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3.
 
Comparative analysis: 
In this section of analysis, I tried to comparatively represent the scenarios of three companies. Here, I have 
included the basic elements of income statements and balance sheets to compare their performances 
throughout the period of 2008-2012. I have also tried to show the growth trend of these elements for each of 
the companies. From income statement, I have compared the elements like- Net sales, COGS, Gross profit, 
Operating expenses and Net income. From balance sheet I have included elements like- Total equity, Total 
liabilities and Total assets. 
Net sales comparison: 
 
 
2008 2009 2010 2011 2012
GSK 1,888,105 3,023,672 3,632,095 4,735,121 5,553,812
Square 9,820,796 11,462,57 13,471,42 16,054,42 17,959,48
Beximco 4,010,167 4,868,254 6,490,847 7,890,241 9,289,115
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From the net sales comparison of all the three companies, we can see that all of them are having an increase in 
their sales throughout the previous years. However, if we compare we can see that. Square has the highest sales 
compared to other two. Though Beximco and GSK are also having an increase in their sales, it is very low 
compared to Square. From growth rate analysis, we can see that Square has a quite stable growth rate, 
Beximco had a great positive growth in 2010 but again came to its previous stable rate afterwards. Here, GSK 
is seen to have the highest growth rate in 2009 which was because of their introduction of consumer products 
in the market in the fourth quarter of 2008. However, the rate is seen to be fluctuating afterwards.   
COGS comparison: 
 
From the cost of sales comparison of all the three companies, we can see that all of them are having an 
increase in their sales throughout the previous years. As Square is having a huge sale in every year, their cost 
of sales are also high than others. Though Beximco and GSK are also having an increase in their sales, it is 
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very low compared to Square. From growth rate analysis, we can see that Square has a quite stable growth rate 
with a little fluctuation 2011 and 2012; Beximco and GSK are seen to have fluctuating rates over the years. 
Here, GSK needs to improve their performance as their cost of sales is very high compared to their sales. The 
reason behind their increase in cost of sales can be mentioned as their maintenance of high inventory. They 
maintain high inventory to reduce sudden government rule imposition on importing certain products from 
other countries. We can also see fluctuations in the cost of sales growth rate of GSK in alternative years. In 
2009 it happened due to the sudden introduction of consumer goods in 2008, which increased the cost of sales. 
In 2011, the increase took place due to a sudden price exchange rate change. Therefore, they need to be more 
aware about increasing their sales reducing cost. 
Gross profit comparison: 
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From the gross profit comparison of all the three companies, we can see that all of them are having an increase 
in their gross profit throughout the previous years. However, if we compare, we can see that. Square has the 
highest gross profit compared to other two. Though Beximco and GSK are also having an increase, it is very 
low compared to Square. From growth rate analysis, we can see that Square has a quite stable growth rate with 
a slight decrease in 2012, Beximco had a great positive growth in 2010 but again came to its previous stable 
rate afterwards. Here, GSK is seen to have the highest growth rate in 2009 and gradually it is holding a 
fluctuating rate. The growth rate basically changed due to the ups and downs in the net sales and cost of sales 
for each company.So, obviously GSK is in a risky situation here as they are having very fluctuating 
performances over the previous years.  
Operating expense comparison: 
 
 
From the operating expense comparison of all the three companies, we can see that all of them are having an 
increase in their operating expenses throughout the previous years. The chart shows that, Square has been 
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having the highest operating expenses because their sales is also high compared to other two. However, it is 
always good for a company when they can reduce their cost increasing profit. So, a high expense is not always 
a bad scenario if it justifies a company’s sales volume and profit. However, if we compare we can see that. 
Square has the highest sales compared to other two. Though Beximco and GSK are also having an increase in 
their expenses, it is very low compared to Square as their operation is also less. From growth rate analysis, we 
can see that Square has a quite stable growth rate over the years with a big fluctuation in 2012, Beximco is 
securing quite a stable positive growth rate situation. Here, GSK is seen to have the highest positive growth in 
their operating expenses which is not a very good sign as we have seen that their sales is very low to justify 
this huge expenses. This is basically happening due to their huge idle capacity which is they have more fixed 
assets to utilize and increase their production as well as sales. So, GSK needs to consider this issue carefully 
and take necessary measures to reduce their operating expense growth. 
Net income comparison: 
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Net income of a company is one of the biggest indicators to see how it is performing and how much amount 
the company is gaining after deducting all expenses, taxes and interests from their gross profit. From the net 
income comparison of all the three companies, we can see that Square and Beximco is having an increase in 
their income. On the other hand, GSK is seen to have highest income in 2010 which again dropped afterwards. 
So, undoubtedly Square is in the most suitable situation in the market compared to other two. From the growth 
rate analysis, we can see that, Square has always a positive growth rate in their income though the rate is very 
much fluctuating. Beximco had unexpectedly highest growth rate in income in 2010 but again it came to its 
previous flow after 2010. GSK’s performance considering the growth rate in their income is unacceptable as 
they are having a very fluctuating growth in their income and even after 2010; the rate is negative which means 
they are having decrease in their income than previous years. Considering the total scenario, GSK is obviously 
in a risky situation and they need to increase their sales and reduce their costs to come out of this situation.   
Total asset comparison: 
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From the total asset comparison of all the three companies, we can see both Square and Beximco is 
maintaining good current and non-current assets to run their operation. As they have huge sales, they need to 
maintain huge assets. GSK is maintaining very low assets than other two. As their operation is low, their assets 
are also seen to be very low. From growth rate analysis, we can see that Beximco had the highest growth rate 
in their assets in 2010 and Beximco in 2009. Other than these two years, both of the company is having a 
stable growth rate whereas GSK is having a high growth rate in their assets compared to other two. 
Equity comparison: 
 
From the equity analysis of all the three companies, we can see that Beximco and Square both are having quite 
equal rate of equity funding and the rate is increasing with the increase in their operation. Here, GSK is seen to 
be maintaining the lowest rate of equity funding. From the growth rate analysis, we can see that Square’s 
equity funding growth rate is quite stable over the five years whereas Beximco and GSK are having a positive 
growth rate but fluctuating. Necessary information regarding this matter could not be identified. 
 
-
5,000,000 
10,000,000 
15,000,000 
20,000,000 
2008 2009 2010 2011 2012
Th
ou
sa
nd
s
Equity analysis
GSK
Square
Beximco
27.57%
18.68%
2.98%
4.45%
16.13%
19.59%
17.72%
15.85%
4.17%
46.74%
7.22%
7.47%
% change in 2009
% change in 2010
% change in 2011
% change in 2012
Growth rate of equity
Beximco Square GSK
 
 
44 
 
Liability comparison: 
 
In this section of analysis, I tried to comparatively represent the scenarios of three companies. Here, I have 
included the basic elements of income statements and balance sheets to compare their performances 
throughout the period of 2008-2012. I have also tried to show the growth trend of these elements for each of 
 
From the liability analysis of the three companies, we can see that, Square is having quite a stable rate in 
maintaining current and non-current liabilities whereas Beximco is seen to have an increasing trend after a 
huge fluctuation in 2009. It is good that Beximco has been able to reduce their liabilities in recent years. GSK 
is having a slight increase in their liabilities over the years. From the growth rate analysis, we can see that, both 
Beximco and Square has been able to reduce their liability growth rate and in some years it is even negative. 
Necessary information regarding this matter could not be identified. 
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the companies. From income statement, I have compared the elements like- Net sales, COGS, Gross profit, 
Operating expenses and Net income. From balance sheet I have included elements like- Total equity, Total 
liabilities and Total assets. 
4.
  
Ratio analysis: 
Ratio analysis is used to evaluate various aspects of a company’s operating and financial performance such as 
its efficiency, liquidity, profitability and solvency. The trend of these ratios over time is studied to check 
whether they are improving or deteriorating. Ratios are also compared across different companies in the same 
sector to see how they stack up, and to get an idea of comparative valuations. Ratio analysis is a cornerstone of 
fundamental analysis.  
 
 
1. Current ratio:  
It is a liquidity ratio that measures a company's ability to pay short-term debts. The ratio is mainly used to 
give an idea of the company's ability to pay back its short-term liabilities (debt and payables) with its short-
term assets (cash, inventory, receivables). The higher the current ratio, the more capable the company is of 
paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if 
they came due at that point. Higher current ratio definitely indicates that the firm is highly liquid and able 
enough to meet the demands of the creditors. Satisfactory current ratio actually varies from industry to 
industry but in general, if the current ratio lies above 1, it indicates that the business is healthy. If the current 
ratio is below 1, then it means that the current liabilities are higher than the current asset, so the firm can face 
many difficulties while paying back their short term debts. On the other hand, if the current ratio is too high 
then it indicates that the firm has problem in working capital management. Low current ratio does not always 
mean that the firm is at an alarming stage or very near to be bankrupt but of course it is better to maintain a 
standard current ratio in order to be free from liquidity risk. 
  Current ratio: Current Asset/Current Liabilities 
 
2008 2009 2010 2011 2012 
GSK 2.96 3.11 2.59 2.05 1.79 
Square 1.46 2.15 1.50 1.59 1.58 
Beximco 1.10 3.07 2.46 2.70 2.67 
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The graph shows that, all the three companies had their highest current ration in 2009. For GSK, though the 
ratio declined afterwards, it was not below 1.So, it can be said that they always maintain a good current ratio 
to pay off their debts in time. In recent past years, Square has been maintaining a stable current ratio which is 
very much required to maintain a healthy financial position. Moreover, they are maintaining current ratio near 
1 which is risk free and they are also operating successfully without maintain any idle capacity. Beximco is 
also maintaining a good position to be able to pay their current debts. So, we can comment that these 
companies are quite aware about their liabilities and they maintain their assets in ways to pay off their 
obligations in time. 
2. Quick ratio: 
This ratio assesses the capacity of an organization to recover its current liabilities by using the 
organization’s quick assets. Assets which can be easily converted into cash are known as quick assets. 
Quick ratio is also known as Acid-test ratio and it excludes the inventories as inventories are less liquid. 
Quick ratio less than 1 indicates that the firm is currently unable to pay its current debts. A high quick ratio 
is not considered as good always depending on the accounts receivables  
 
and current liabilities. If it happens that the firm has huge account receivables which will be collected after a 
long time and the current liabilities are lesser but needs to be paid instantly then the quick ratio will be 
higher. However, the firm will be in a risky situation as there is liquidity crisis. On the other hand, opposite 
thing can also happen.  
Quick Ratio: (Current Assets-Inventories) ∕ Current Liabilities 
 2008 2009 2010 2011 2012 
GSK 1.23 1.69 1.60 0.95 1.05 
2008 2009 2010 2011 2012
GSK 2.96 3.11 2.59 2.05 1.79
Square 1.46 2.15 1.50 1.59 1.58
Beximco 1.10 3.07 2.46 2.70 2.67
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Square 0.66 1.16 0.96 0.95 0.92 
Beximco 0.52 2.31 1.67 1.83 1.88 
 
 
 
 
The graph shows that GSK Bangladesh had highest quick ratio in 2009 which declined in 2010 and 2011. In 
2011, the ratio was less than 1 which was not pleasing. However, in 2012 it again increased indicating a good 
liquid position. Compared to GSK, Square also had the highest ratio in 2009 which gradually decreased 
afterwards. From, 2010 to 2012, the ratios are less than 1 which is not satisfactory. In case of Beximco also the 
ratio was highest in 2009 and they held a very good ratio in all years compared to other twos. Compared to 
their liquid assets, their illiquid assts are very low. So, they have a good quick ratio. Finally, the graph shows 
that, GSK has maintained satisfactory ratios in past years as well as recent years indicating their good ability of 
paying off their current debts with their current liquid assets.  
3. Cash ratio: Cash ratio is a ratio of a firm’s cash and cash equivalents to its current liabilities. This ratio is a 
great measurement of liquidity. If the ratio is high then it indicates that the firm has enough cash to meet up 
immediate payment demand. The cash ratio is generally a more conservative look at a company's ability to 
cover its liabilities than many other liquidity ratios. This is due to the fact that inventory and accounts 
receivable are left out of the equation. Cash ratio is very conservative at its appearance as it does not include 
inventories and accounts receivables, only cash on hand and cash equivalents are used to calculate this. Since 
these two accounts are a large part of many companies, this ratio should not be used in determining company 
value, but simply as one factor in determining liquidity. 
Cash ratio: Cash & Equivalents/Current Liabilities 
  2008 2009 2010 2011 2012 
GSK 0.01 0.73 0.95 0.75 0.71 
Square 0.11 0.12 0.08 0.14 0.25 
2008 2009 2010 2011 2012
GSK 1.23 1.69 1.60 0.95 1.05
Square 0.66 1.16 0.96 0.95 0.92
Beximco 0.52 2.31 1.67 1.83 1.88
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Beximco 0.03 0.47 0.59 0.20 0.18 
 
 
The graph shows that, in 2008, the cash ratio was very poor which signals that GSK faced much liquidity crisis 
and had not sufficient cash in hand to pay back the short term liabilities. However, GSK is maintaining a good 
cash ratio from 2009 to 2012 and it is also high in all years compared to other two companies.  Square had 
their highest cash ratio in 2012 but compared to other two it is having the lowest ratio. Beximco improved their 
liquidity position in recent years and it can be mentioned as quite satisfactory. 
4. Gross profit margin: 
The relationship of sales and cost of goods sold is assessed through gross profit margin. High ratio indicates a 
secure position for the company. Low profit margin signals towards less safe position because it means that 
sales are diminishing, therefore generating low revenues. The gross margin is not an exact estimate of the 
company's pricing strategy but it does give a good indication of financial health. Without an adequate gross 
margin, a company will be unable to pay its operating and other expenses and build fund for the future. It helps 
to cut cost by presenting that cost as relatively low or high than the revenues. So, from the low profit margin a 
company gets the idea of increasing their revenues or decreasing their direct costs. 
Gross profit margin: Gross Profit/Net Sales 
  2008 2009 2010 2011 2012 
GSK 24.98% 31.23% 34.20% 28.48% 28.61% 
Square 42.24% 42.76% 42.81% 42.90% 43.07% 
Beximco 50.06% 47.29% 48.89% 47.99% 47.25% 
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The graph shows that, all the three companies tried to maintain a stable gross profit margin in past years. 
Though for GSK, a little fluctuation in the margin can be seen, but they are also trying to increase their sales 
over the cost of sales. For both Square and Beximco, it can be commented that they are satisfactorily 
maintaining a stable profit margin throughout the past years and here Square’s performance is outstanding 
regarding very less fluctuation in their performance. 
5. Operating Profit Margin:  
This ratio is another important tool to measure a company's profitability and operating efficiency. Operating 
margin is a measurement of what proportion of a company's revenue is left over after paying for variable costs 
of production such as wages, raw materials, etc. A healthy operating margin is required for a company to be 
able to pay for its fixed costs, such as interest on debt and taxes..This profit is also known as Earnings before 
Interest and Tax (EBIT). This operating profit is used to calculate the operating profit margin which clarifies 
how efficiently and effectively the firm is doing operations and making money. High operating profit margin 
indicates that the firm is good at merchandising activities, they are low cost producers so capable to offer 
cheap price to the customers and in this manner they are making high profit than their competitors. The 
operating profit margin, also clarifies how much operating profit a company makes on each dollar of sales. 
Higher operating profit margin indicates a healthy business. 
Operating Profit Margin: EBIT/Net Sales 
  2008 2009 2010 2011 2012 
GSK 10.84% 14.51% 15.22% 9.83% 7.37% 
Square 25.57% 24.65% 25.35% 24.78% 24.95% 
Beximco 17.81% 17.82% 20.98% 21.26% 20.56% 
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From the trend we can see that, Square is in the best position compared to its competitors. It is maintaining the 
highest and the most stable level of operating margin for the last few years. The scenario for GSK is not so 
good. Though in 2008 and 2009, the margin increased, but it again declined in 2011 and 2012. The rate is also 
very low compared to its competitors indicating poor management and pricing strategy. Beximco has been 
maintain a stable margin, but less satisfactory than Square. 
6. Net Profit Margin:  
A ratio of profitability calculated as net income divided by revenues, or net profit divided by sales. It measures 
how much out of every dollar of sales a company actually earns. This is also known as profit margin. Higher 
the profit margin, better the condition of the firm. Higher profit margin means that higher portion is remaining 
as profit after the selling activity takes place. So it also indicates towards efficient expense controlling ability. 
Increased earnings are good, but an increase in sales does not mean that the profit margin of a company is 
improving. For instance, if a company has costs that have increased at a greater rate than sales, it leads to a 
lower profit margin. This is an indication that costs need to be under better control. 
Net Profit Margin: Net Income/Net Sales 
  2008 2009 2010 2011 2012 
GSK 7.57% 10.71% 11.29% 5.96% 4.39% 
Square 19.25% 18.21% 19.48% 18.92% 18.04% 
Beximco 13.60% 12.83% 16.20% 15.19% 14.20% 
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The graph shows that, GSK is having a drastic decline in their net profit margin in recent years (2011-2012). 
Though the rate was seen to be improving in 2009 and 2010, it again declined afterwards. Square is seen to be 
in the most satisfactory situation compared to its competitors. It has been maintain the most stable performance 
and the rate is also higher in every years. In case of Beximco, we can see that the rate has increased than 
previous years but not so much compared to its one of the big competitors Square. From all these three 
companies comparison, it is quite clear that GSK needs to pay more attention in increasing their performance 
to compete and run their operations successfully.  
7. Return on Asset:  
Return on asset is an indicator of how profitable a company is relative to its total assets. ROA gives an idea of 
how competent management is at using its assets to generate earnings. It is calculated by dividing a company's 
annual earnings by its total assets, ROA is displayed as a percentage. Sometimes this is referred to as "return 
on investment". The assets of the company are comprised of both debt and equity. Both of these types of 
financing are used to fund the operations of the company. The ROA figure gives investors an idea of how 
effectively the company is converting the money it has to invest into net income. The higher the ROA number, 
the better, because the company is earning more money on less investment. 
Return on Asset: Net Income/Total Assets 
  2008 2009 2010 2011 2012 
GSK 10.49% 19.03% 18.52% 10.84% 7.96% 
Square 14.26% 13.89% 13.50% 14.16% 13.82% 
Beximco 3.68% 3.14% 4.92% 5.20% 5.37% 
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The graph interprets that, GSK had great improvement in early years from 2008-2010. However, in recent 
years the return on assets rate went down. So, GSK’s performance here is not stable and in declining trend 
which is a matter of much concern. Square’s trend shows that its performance is quite good and in a stable 
position. Beximco is the lowest in all years compared to its competitors. It indicates that they are generating 
lowest amount of return from their investments in assets. Compared to other companies in the industry, GSK 
should focus on increasing their performance and try to keep it stable. 
 
8. Return on Equity:  
Return on Equity or ROE is the ratio of net income to total shareholder’s equity. It measures how much a firm 
earns from the shareholders’ equity. It also shows the firm’s efficiency at generating profits from every dollar 
of equity capital. Increasing ROE indicates improved performance. In accounting sense, ROE is the true 
bottom line of performance measurement. 
Return on Equity: Net Income/Shareholders' equity 
  2008 2009 2010 2011 2012 
GSK 15.67% 27.82% 29.70% 19.83% 16.42% 
Square 19.00% 18.07% 18.99% 18.67% 17.19% 
Beximco 5.22% 5.74% 6.58% 7.00% 7.17% 
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The graph shows, GSK had the highest return on equity from 2008-2010 compared to its competitors. So, it 
generated the highest return from their shareholders’ equity. However, from 2011 it started decreasing which is 
not a good sign for the management. They need to be concerned about improving their return on equity. On the 
other hand, though Square didn’t have high returns, it can be seen as maintaining a stable rate of return. 
Beximco is seen to have the lowest percentage of returns consistently. Their performance is very poor 
throughout the past few years indicating a lower return generated from shareholders’ equity. 
9. Asset turnover:  
Asset Turnover measures how much sales revenue is gathered in against each dollar of assets. It indicates the 
efficiency of asset management of a firm. Higher the ratio, higher the efficacy of the firm.  If a company can 
generate more sales with fewer assets it has a higher turnover ratio which tells it is a good company because it 
is using its assets efficiently. A lower turnover ratio tells that the company is not using its assets optimally. 
Asset turnover: Sales/Total Assets 
 2008 2009 2010 2011 2012 
GSK 1.39 1.78 1.78 1.82 1.81 
Square 0.74 0.76 0.69 0.75 0.77 
Beximco 0.27 0.24 0.30 0.34 0.38 
 
2008 2009 2010 2011 2012
GSK 15.67% 27.82% 29.70% 19.83% 16.42%
Square 19.00% 18.07% 18.99% 18.67% 17.19%
Beximco 5.22% 5.74% 6.58% 7.00% 7.17%
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The graph shows that, GSK Bangladesh is in a very good position in case of generating revenues against each 
dollars of asset. The asset management of this company is outstanding compared to other two big competitors 
and their performance is quite stable throughout the past few years. With fewer amount of assets, they have 
been able to generate huge profits utilizing their assets fully. On the other hand, Square and Beximco both had 
turnovers less than 1 for the past few years which indicates less satisfactory asset management. It indicates 
that, they are not utilizing their existing assets perfectly to generate enough profits. 
10. Inventory turnover:  
Sufficient amount of inventory is must to do successful business. This ratio basically shows that over a 
period, how many times the inventories are sold and renovated. Generally, a company with high 
inventory turnover ratio is assumed as strong one. When the inventory level is very high, the ratio will 
be low which means poor sales and the inventories are kept idle in the warehouse. Definitely, it is bad 
for future growth of the company. The turnover ratio for perishable good is normally very high as these 
are sold out quickly. Although high inventory turnover ratio is desirable, sometimes it may indicate 
ineffective buying.  
Inventory turnover: Sales / Inventory 
 
 
  2008 2009 2010 2011 2012 
GSK 3.17 4.95 5.22 4.16 5.24 
Square 4.68 5.19 5.30 5.97 7.17 
Beximco 2.66 2.83 3.27 3.44 3.82 
 
2008 2009 2010 2011 2012
GSK 1.39 1.78 1.78 1.82 1.81
Square 0.74 0.76 0.69 0.75 0.77
Beximco 0.27 0.24 0.30 0.34 0.38
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Trend from the graph shows that, GSK is maintaining a stable ratio and it’s quite good compared to other two 
companies. However, the cost of goods sold says they have huge unused inventories which increase the cost 
reducing profit. So, they need to be careful in maintaining sufficient inventories but not excessive to meet up 
the needs. Square was also maintaining a quite stable performance from 2008-2011. In 2012, the ratio is the 
highest so their performance improved in this year. Beximco has been having the lowest turnover ratios in all 
years compared to its competitors. So, they should consider improving their performance now. 
11. Debt ratio:  
This ratio finds out how much of the total asset is funded through debt. A debt ratio greater than 1 indicates 
that a company has more debt than assets and it is more dependent to its creditors for necessary financing. 
Meanwhile, a debt ratio of less than 1 indicates that a company has more assets than debt. The higher this ratio, 
the more leveraged the company and the greater its financial risk. Although higher debt is not a problem if 
interest payments are made on time, but if it is not then definitely a great risk for the firm. 
Debt ratio: Total debt/Total assets 
  2008 2009 2010 2011 2012 
GSK 0.33 0.32 0.38 0.45 0.52 
Square 0.25 0.23 0.29 0.24 0.20 
Beximco 0.29 0.45 0.25 0.26 0.25 
 
2008 2009 2010 2011 2012
GSK 3.17 4.95 5.22 4.16 5.24
Square 4.68 5.19 5.30 5.97 7.17
Beximco 2.66 2.83 3.27 3.44 3.82
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The trend shows that, GSK had an increase in debt financing for the past few years. In 2012, they had the 
highest rate 0.52 of debt financing. From Square’s trend we can see that, in 2010 it had the highest rate and 
now gradually they are focusing on decreasing their debt ratio which is a good sign in a sense that they are now 
relying less on their creditors for financing. On the other hand, Beximco had their highest rate in 2009, but 
they tactfully handled that situation to decrease their debt financing in past few years. However, GSK should 
be concerned about this scenario as their ratio is higher than their competitor which is not a very good sign. 
12. Debt to equity ratio:  
The debt-to-equity ratio is a measure of the relationship between the capital invested by creditors and the 
capital contributed by shareholders. Lower values of debt-to-equity ratio are favorable indicating less risk. 
Higher debt-to-equity ratio is unfavorable because it means that the business relies more on external lenders 
thus it is at higher risk, especially at higher interest rates. A debt-to-equity ratio of 1 means that half of the 
assets of that business is financed by debt and half by shareholders' equity. A value higher than 1 means more 
assets are financed by debt than those financed by money of shareholders' and vice versa. An increasing trend 
in of debt-to-equity ratio is also alarming because it means that the percentage of assets of a business which are 
financed by the debts is increasing. Higher debt can lead to both higher gain and risk, so firms should be very 
careful while taking financial leverage. 
Debt to equity ratio: Total debt/Total equity 
  2008 2009 2010 2011 2012 
GSK 0.49 0.46 0.60 0.83 1.06 
Square 0.33 0.30 0.41 0.32 0.24 
Beximco 0.42 0.82 0.34 0.34 0.34 
2008 2009 2010 2011 2012
GSK 0.33 0.32 0.38 0.45 0.52
Square 0.25 0.23 0.29 0.24 0.20
Beximco 0.29 0.45 0.25 0.26 0.25
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The trend from graph shows that, GSK is gradually having an increase in its debt financing. In 2012, it is even 
higher than 1 which is a matter of concern as they are relying more on external lenders and it can be a threat if 
interest rate increases. They should be careful about their financing now. The performance trend of Square is 
lower than both of its big competitors. So, it can be said to have a good position in the industry regarding its 
low debt financing as it is facing lower risk. On the other hand, Beximco is maintaining their debt financing 
position quite constantly for the past few years and it has also reduced than previous years. 
13. EPS (Earning Per Share):  
Earning per share or EPS expresses the earned profit against each share. It is considered as an important tool 
while measuring a company’s stock performance. Investors often judge firms with the EPS and always prefer a 
high EPS. However, always high EPS does not mean that the firm is doing well because the net income can be 
manipulative which makes the EPS overestimated. Often firms do these in order to attract more public 
investments. So, relying only on EPS is never a wise decision. Another important point is, same EPS of two 
firms do not indicate that the firms are equally strong; here we need to judge which firm has earned same EPS 
by less investment. The firm which has done so is in better position and more efficient than the other. 
EPS (Earning Per Share): Net Income/No. of shares outstanding  
  2008 2009 2010 2011 2012 
GSK 11.87 26.88 34.05 23.41 20.25 
Square 125.25 138.36 129.07 10.94 9.01 
Beximco 3.61 4.13 5.17 3.93 4.33 
2008 2009 2010 2011 2012
GSK 0.49 0.46 0.60 0.83 1.06
Square 0.33 0.30 0.41 0.32 0.24
Beximco 0.42 0.82 0.34 0.34 0.34
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Graph shows, from 2008-2011, Square had the highest earning per share indicating their huge earnings 
on less investment. Their net income was high compared to their number of shares outstanding. During 
this five year period, their net income and number of shares both increased and in 2011 and 2012 EPS 
felt down drastically due to issue of huge number of new shares by the company. GSK had the highest 
EPS in 2010 and the lowest in 2008, 11.87. Beximco is consistently having very low EPS compared to 
Square and GSK. 
14. Dividend payout ratio:  
The dividend payout ratio is actually the percentage of earnings that is given to the investors of the firm. High 
payout ratio always attracts the investors because it means that the firm is in good position and generating huge 
profit. So, investors always seek for high stock dividends and often switch to another stock in order to have 
their desired dividend. It is not always true that firms in good condition can only afford dividend payment, it 
may also happen that a firm with a future growth prospect currently giving low or zero dividends will provide 
the investors high capital gain in future. So, investors should not only seek high dividends, they should be 
more aware about high capital gain. Sometimes, excess amount dividend payment is a bad sign, it indicates 
that organization is giving away money to attract more investors rather than reinvesting again in operational 
activities. 
Dividend payout ratio: Total Dividend/ Net Income 
  2008 2009 2010 2011 2012 
GSK 51% 60% 59% 64% 74% 
Square 25% 30% 35% 40% 30% 
Beximco 30% 15% 20% 21% 15% 
2008 2009 2010 2011 2012
GSK 11.87 26.88 34.05 23.41 20.25
Square 125.25 138.36 129.07 10.94 9.01
Beximco 3.61 4.13 5.17 3.93 4.33
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The graph shows that, GSK Bangladesh has the highest dividend payout ratios which are helping to attract 
investors to invest in stocks. In 2012, the ratio was the highest. Square has dividend payout ratios between 
GSK and Beximco. However, Beximco has the lowest payout ratio throughout the past few years. 
15. Price Earnings ratio (P/E):  
A valuation ratio of a company's current share price compared to its per-share earnings. The P/E ratio actually 
represents the expectation of investors about the firm. Higher P/E means that investors have high expectations 
about the firm’s future growth and that’s why they are interested to invest. P/E ratio also sometimes indicates 
how much the investors are willing to pay for each dollar of earnings. So, in this case it is referred as multiple. 
The average P/E ratio is 20-25 times. Comparing P/E ratio within firms of same industry gives the idea of 
which firm is performing well. 
Price Earnings ratio (P/E): Market price per share/EPS 
  2008 2009 2010 2011 2012 
GSK 27.81 26.98 33.17 28.37 28.15 
Square 30.46 33.65 25.35 21.69  19.82 
Beximco 46.45 44.51 32.32 23.82 12.91 
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Trend shows that, over the last five years, the P/E ratio of GSK has been quite high which means that investors 
have great interest on GSK’s stock. This is because GSK is a well reputed multinational firm and has a unique 
brand image. The ratio was highest in 2010 and lowest but well above from the standard in 2009. Square is 
seen to have the highest rate in 2oo9 and the trend shows that the rate is decreasing which is not a very good 
sign for the company’s stock. However, Beximco here is seen to have the highest rates in past few years. 
Compared to GSK and Square, it can be seen that people prefer to invest in Beximco’s stock but it is alarming 
that they are also having a severe decrease in their rate in the last year. 
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CHAPTER FIVE 
 

 As a multinational company, GSK is now earning revenue both for selling medicinal products and 
consumer goods. However, compared to its sales of medicinal products, consumer products like- Horlicks, 
Sensodyne etc. products have much demand. Thus, the revenue earned from consumer products are more 
compared to pharmaceutical products. This has diluted the position of GSK in the pharmaceutical industry. 
So, they should try more to give the same effort to promote their pharmaceutical products for earning 
greater revenues from this industry and compete successfully with their competitors, grabbing a strong 
market share and market position.
 GSK maintains a very huge amount of idle inventories to reduce risk. Due to having risk of sudden 
imposition of new rules from the government, they try to maintain excess inventories so that they can fulfill 
market demand if any adverse situation arises. This maintenance of huge inventory is causing them 
increasing their cost of sales decreasing their profit. So, they should consider this matter seriously and 
maintain not excessive but necessary amount of inventory.
 Due to maintaining good quality products and acquiring raw materials from specific sources only, 
their raw material purchase price remains more than their local competitors. This is obviously one of the 
biggest problems. Bangladesh is a developing country so every people here cannot afford expensive 
medicines made by the best quality raw materials. So, they go for buying the substitute medicines made by 
the local companies with less expensive products. Thus, GSK pharmaceutical products are losing their 
market, sales and profit. To reduce cost of purchase they can think about cheaper sources to purchase raw 
materials without compromising the quality. Moreover, they can also focus on differentiation and focus 
strategy to come up with unique products to serve their customers and increase demand for their unique 
medicines. 
 The promotional activity carried out by GSK to sell their pharmaceutical products is not sufficient 
enough to let people know about the medicines and increase their demands. As a multinational company, 
they have some restrictions from the headquarter to not persuade the doctors to prescribe their medicines to 
their patients. On December 17, 2013, GSK announced that it would cease compensating doctors for 
prescribing the company’s products, would stop paying professionals for speaking at medical conferences, 
and would remove prescription-related sales targets for its reps. On the other hand; other local companies 
use those strategies to increase the demands of their medicines. Moreover, they are also seen to use some 
illegal means like- bribing doctors to prescribe their medicines and thus increase sales of those medicines. 
This scenario obviously possesses some challenge to the multinational companies in increasing the demand 
for their products. Obviously, it is appreciable that they are not using any illegal means to sell their 
products, but to survive in the market successfully they must come up with some new legal promotional 
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strategies to increase awareness of their product and and thus increase their profit.
 Although GSK is maintaining a fair current ratio, but from 2008 to 2012 it is gradually decreasing 
which is an indication that current liabilities are increasing. So, GSK must concentrate on this issue and 
should be careful to control their debts. Compared to GSK, Beximco is seen to have an increasing current 
ratio trends but Square is having the lowest ratios in all years which says that Square has less liquid assets 
to pay off their debts than the  other two companies. However, this also indicates that Square does not allow 
any idle capacity to increase cost. GSK can also follow this strategy to decrease their idle capacity and thus 
utilize necessary capacity to fulfill demand and decrease extra cost.
 Most of the profitability ratios like- gross profit margin, operating profit margin and net profit 
margin, GSK is seen to have a very low percentage compared to its competitors. So, it means that the 
growth in profit of GSK is lowering day by day. Earning profit is the main objective of doing any business. 
So, in this case GSK must think how more profit can be achieved and find ways to capture the significant 
portion of the market by increasing their market share.
 The debt ratio of GSK is not so high but it is increasing gradually and in 2012 it was .52. Although 
the figure is not so big but a value below .5 is more secured. So, from now, GSK should see if their 
dependencies on their trade creditors are increasing or not. If it is increasing, then they must take effective 
steps to reduce it.
 There is an upward trend in debt to equity ratio, again pointing out that debts are increasing. 
Although higher debts can give financial leverage but there is also a risk of meeting up the debt obligations. 
So, they should realize that higher debts can lead to higher risk. From now it should be little conservative in 
case of taking debts. 
 Market coverage can be expanded through reaching every corner of the country. GSK needs to adopt 
more aggressive strategy in order to beat the competitors. 
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CHAPTER SIX 
 
 
 
Conclusion: 
Financial ratios analysis is a part of financial statement analysis through which the performance of a 
company’s past and present position is measured. Most importantly, it gives an idea about the company’s 
performance in the future. Ratio analysis involves the calculation of statistical relationship between data and it 
is a very popular technique of financial statement analysis. Throughout my analysis, I came to know about the 
financial strength, operational efficacy and management efficacy of GSK, Square and Beximco. I have realized 
GSK’s position compared to its competitors and I have seen that they are performing well. It is financially 
solvent but still there are some threats which need to be handled properly to survive and have more successful 
position in the industry.  
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